Deep brain and cortical stimulation for epilepsy by Sprengers, Mathieu et al.
Deep brain and cortical stimulation for epilepsy (Review)
Sprengers M, Vonck K, Carrette E, Marson AG, Boon P
This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library
2014, Issue 6
http://www.thecochranelibrary.com
Deep brain and cortical stimulation for epilepsy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
8BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
11RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Figure 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Figure 5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Figure 6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
25ADDITIONAL SUMMARY OF FINDINGS . . . . . . . . . . . . . . . . . . . . . . . . . .
40DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
43AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
45ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
45REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
48CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
75DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Stimulation versus sham stimulation, Outcome 1 Seizure freedom. . . . . . . . . 77
Analysis 1.2. Comparison 1 Stimulation versus sham stimulation, Outcome 2 Responder rate. . . . . . . . . 78
Analysis 1.3. Comparison 1 Stimulation versus sham stimulation, Outcome 3 Seizure frequency reduction. . . . . 79
Analysis 1.4. Comparison 1 Stimulation versus sham stimulation, Outcome 4 Quality of Life. . . . . . . . . 81
Analysis 2.1. Comparison 2 Stimulation versus sham stimulation - sensitivity analyses, Outcome 1 Seizure freedom RR. 82
Analysis 2.2. Comparison 2 Stimulation versus sham stimulation - sensitivity analyses, Outcome 2 Responder rate RR. 83
Analysis 2.3. Comparison 2 Stimulation versus sham stimulation - sensitivity analyses, Outcome 3 Seizure freedom OR
0.25. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
Analysis 2.4. Comparison 2 Stimulation versus sham stimulation - sensitivity analyses, Outcome 4 Responder rate OR
0.25. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
Analysis 2.5. Comparison 2 Stimulation versus sham stimulation - sensitivity analyses, Outcome 5 Seizure freedom RR
0.25. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
Analysis 2.6. Comparison 2 Stimulation versus sham stimulation - sensitivity analyses, Outcome 6 Responder rate RR
0.25. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
87APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
89CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
89DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
89SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
90DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
iDeep brain and cortical stimulation for epilepsy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Deep brain and cortical stimulation for epilepsy
Mathieu Sprengers1, Kristl Vonck1, Evelien Carrette1, Anthony G Marson2 , Paul Boon1
1Department of Neurology, Ghent University Hospital, Ghent, Belgium. 2Department of Molecular and Clinical Pharmacology,
Institute of Translational Medicine, University of Liverpool, Liverpool, UK
Contact address: Paul Boon, Department of Neurology, Ghent University Hospital, 1K12, 185 De Pintelaan, Ghent, B-9000, Belgium.
Paul.Boon@UGent.be.
Editorial group: Cochrane Epilepsy Group.
Publication status and date: New, published in Issue 6, 2014.
Review content assessed as up-to-date: 6 August 2013.
Citation: Sprengers M, Vonck K, Carrette E, Marson AG, Boon P. Deep brain and cortical stimulation for epilepsy. Cochrane Database
of Systematic Reviews 2014, Issue 6. Art. No.: CD008497. DOI: 10.1002/14651858.CD008497.pub2.
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Despite optimal medical treatment, including epilepsy surgery, many epilepsy patients have uncontrolled seizures. In the last decades,
interest has grown in invasive intracranial neurostimulation as a treatment for these patients. Intracranial stimulation includes both
deep brain stimulation (DBS) (stimulation through depth electrodes) and cortical stimulation (subdural electrodes).
Objectives
To assess the efficacy, safety and tolerability of deep brain and cortical stimulation for refractory epilepsy based on randomized controlled
trials.
Search methods
We searched PubMed (6 August 2013), theCochrane EpilepsyGroup Specialized Register (31 August 2013), Cochrane Central Register
of Controlled Trials (CENTRAL) (The Cochrane Library 2013, Issue 7 of 12) and reference lists of retrieved articles. We also contacted
device manufacturers and other researchers in the field. No language restrictions were imposed.
Selection criteria
Randomized controlled trials (RCTs) comparing deep brain or cortical stimulation to sham stimulation, resective surgery or further
treatment with antiepileptic drugs.
Data collection and analysis
Four review authors independently selected trials for inclusion. Two review authors independently extracted the relevant data and
assessed trial quality and overall quality of evidence. The outcomes investigated were seizure freedom, responder rate, percentage
seizure frequency reduction, adverse events, neuropsychological outcome and quality of life. If additional data were needed, the study
investigators were contacted. Results were analysed and reported separately for different intracranial targets for reasons of clinical
heterogeneity.
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Main results
Ten RCTs comparing one to three months of intracranial neurostimulation to sham stimulation were identified. One trial was on
anterior thalamic DBS (n = 109; 109 treatment periods); two trials on centromedian thalamic DBS (n = 20; 40 treatment periods),
but only one of the trials (n = 7; 14 treatment periods) reported sufficient information for inclusion in the quantitative meta-analysis;
three trials on cerebellar stimulation (n = 22; 39 treatment periods); three trials on hippocampal DBS (n = 15; 21 treatment periods);
and one trial on responsive ictal onset zone stimulation (n = 191; 191 treatment periods). Evidence of selective reporting was present
in four trials and the possibility of a carryover effect complicating interpretation of the results could not be excluded in 4 cross-over
trials without any washout period.
Moderate-quality evidence could not demonstrate statistically or clinically significant changes in the proportion of patients who were
seizure-free or experienced a 50% or greater reduction in seizure frequency (primary outcome measures) after 1 to 3 months of anterior
thalamic DBS in (multi)focal epilepsy, responsive ictal onset zone stimulation in (multi)focal epilepsy patients and hippocampal DBS
in (medial) temporal lobe epilepsy. However, a statistically significant reduction in seizure frequency was found for anterior thalamic
DBS (-17.4% compared to sham stimulation; 95% confidence interval (CI) -32.1 to -1.0; high-quality evidence), responsive ictal onset
zone stimulation (-24.9%; 95% CI -40.1 to 6.0; high-quality evidence) ) and hippocampal DBS (-28.1%; 95% CI -34.1 to -22.2;
moderate-quality evidence). Both anterior thalamic DBS and responsive ictal onset zone stimulation do not have a clinically meaningful
impact on quality life after three months of stimulation (high-quality evidence).
Electrode implantation resulted in asymptomatic intracranial haemorrhage in 3% to 4% of the patients included in the two largest
trials and 5% to 13% had soft tissue infections; no patient reported permanent symptomatic sequelae. Anterior thalamic DBS was
associated with fewer epilepsy-associated injuries (7.4 versus 25.5%; P = 0.01) but higher rates of self-reported depression (14.8 versus
1.8%; P = 0.02) and subjective memory impairment (13.8 versus 1.8%; P = 0.03); there were no significant differences in formal
neuropsychological testing results between the groups. Responsive ictal-onset zone stimulation was well tolerated with few side effects
but SUDEP rate should be closely monitored in the future (4 per 340 [= 11.8 per 1000] patient-years; literature: 2.2-10 per 1000
patient-years). The limited number of patients preclude firm statements on safety and tolerability of hippocampal DBS.
With regards to centromedian thalamic DBS and cerebellar stimulation, no statistically significant effects could be demonstrated but
evidence is of only low to very low quality.
Authors’ conclusions
Only short term RCTs on intracranial neurostimulation for epilepsy are available. Compared to sham stimulation, one to three months
of anterior thalamic DBS ((multi)focal epilepsy), responsive ictal onset zone stimulation ((multi)focal epilepsy) and hippocampal
DBS (temporal lobe epilepsy) moderately reduce seizure frequency in refractory epilepsy patients. Anterior thalamic DBS is associated
with higher rates of self-reported depression and subjective memory impairment. SUDEP rates require careful monitoring in patients
undergoing responsive ictal onset zone stimulation. There is insufficient evidence to make firm conclusive statements on the efficacy
and safety of hippocampal DBS, centromedian thalamic DBS and cerebellar stimulation. There is a need for more, large and well-
designed RCTs to validate and optimize the efficacy and safety of invasive intracranial neurostimulation treatments.
P L A I N L A N G U A G E S U M M A R Y
Intracranial electrical stimulation to treat drug-resistant epilepsy
Despite many antiepileptic drugs being available, about 30% of epilepsy patients are not seizure-free. Electrical stimulation through
intracranially implanted electrodes has been proposed as an alternative treatment for these patients. This review aimed to evaluate its
efficacy, safety and tolerability. Various brain structures have been targeted with scheduled (that is seizure-independent) stimulation,
including the anterior thalamic nucleus (1 trial, 109 participants), the centromedian thalamic nucleus (2 trials, 20 participants), the
cerebellar cortex (3 trials, 22 participants) and the hippocampus (3 trials, 15 participants). In addition, one trial (191 participants)
studied responsive stimulation (that is only upon seizure detection) of the seizure onset zone. There is evidence for moderate (15% to
30%) seizure frequency reduction after short-term (one to three months) anterior thalamic nucleus stimulation in (multi)focal epilepsy,
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hippocampal stimulation in temporal lobe epilepsy, and responsive seizure onset zone stimulation in (multi)focal epilepsy. However,
there is no evidence for significant impact on seizure freedom, the proportion of patients with a greater than 50% seizure frequency
reduction, or quality of life. Adverse effects of anterior thalamic stimulation include self-reported depression and subjective memory
impairment, and possibly anxiety and confusional state. Responsive seizure onset zone stimulation was well tolerated with few side
effects but the sudden unexplained death in epilepsy (SUDEP) rate was slightly elevated in the (for this purpose) small trial and should
be closely monitored in further studies. There is insufficient evidence to make firm conclusive statements on the efficacy or side effects
of hippocampal, centromedian thalamic and cerebellar cortical stimulation. Intracranial implantation of the electrodes was relatively
safe without permanent symptomatic sequelae in the patients included in the trials. More larger and well-designed trials on intracranial
electrical stimulation treatments are needed to validate and optimize its efficacy and safety and to compare this treatment to currently
available treatments (for example antiepileptic drugs).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Anterior thalamic nucleus stimulation for refractory epilepsy
Patient or population: adults with IQ >70 with refractory focal epilepsy
Settings: epilepsy centers in the United States
Intervention: anterior thalamic nucleus stimulation
Comparison: sham stimulation
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Sham stimulation Anterior Thalamic Nu-
cleus stimulation
Seizure freedom
(3-month blinded evalua-
tion period)
Observed in Fisher 2010 OR 0.33 (0.01 to 8.35) 109
(1)
⊕⊕⊕©
moderate1
1 per 55 0 per 54
(0 to 7)
Low risk population
1 per 1000 0 per 1000
(0 to 8)
High risk population
15 per 1000 5 per 1000
(0 to 113)
Responder rate
(3-month blinded evalua-
tion period)
26 per 100 30 per 100
(15 to 49)
OR 1.20 (0.52 to 2.80) 109
(1)
⊕⊕⊕©
moderate1
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Seizure frequency re-
duction (%)
(3-month blinded evalua-
tion period)
Median monthly
seizure frequency reduc-
tions ranged from -14.5
to -28.7%
The mean seizure fre-
quency in the intervention
group was
-17.4% lower
(-31.2 to -1.0% lower)
109 (1) ⊕⊕⊕⊕
high2
A trend for increasing ef-
ficacy over time was ob-
served during the blinded
evaluation period and
could result into an un-
derestimation of the treat-
ment effect (treatment ef-
fect of month 3: -29%)
Adverse events See comment See comment 109 (1) ⊕⊕⊕©
moderate1
Stimulation-related ad-
verse events during the
blinded evaluation period
include (stimulation ver-
sus control): depression
(14.8 versus 1.8%, P=
0.02), subjective mem-
ory impairment (13.8 ver-
sus 1.8%, P=0.03) and
epilepsy-related injuries
(7.4 versus 25.5%, P=0.
01). Standard stimulation
parameters could be in-
appropriate and increase
seizure frequency in a
small minority of patients.
4
Asymptomatic intracra-
nial haemorrhages oc-
curred in 3.7%of subjects
after the initial implant
procedure. In 8.2%of par-
ticipants leads had to be
replaced after initial im-
plantation outside the tar-
get. During long-term fol-
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low-up, uncontrolled im-
plant site infections (12.
7%) urged hardware re-
moval in 8.2% of sub-
jects. Two SUDEPs oc-
curred over 325 p-y with
stimulation (6.2 per 1000
p-y) which is compara-
ble to rates reported in re-
fractory epilepsy popula-
tions (2.2-10 per 1000 p-
y) (Tellez-Zenteno 2005;
Tomson 2008).
Neuropsychological out-
come
(3 months)
See comment See comment 96-100 (1) ⊕⊕⊕©
moderate5
Changes in neuropsycho-
logical test scores for
cognition and mood were
very similar in the treat-
ment and control group
and not significantly dif-
ferent. Individual patient
data show worsening (>
1 SD) of Profile of Mood
States Depression sub-
scale (POMS-D) in 3/8
stimulated subjects with
self-reported depression
and 0/7 patients with sub-
jective memory impair-
ment showed worsening
(> 1 SD) of verbal or vi-
sual memory scores
Quality of life
(QOLIE-31)
(3 months)
The mean improvement
of the QOLIE-31 score
in the control group was
+2.8
Themean improvement in
QOLIE-31 score in the in-
tervention group was
-0.30 lower
(-3.50 lower to +2.90
105 (1) ⊕⊕⊕⊕
high
Positive changes in
QOLIE-31 (quality of
life in epilepsy 31)
scores indicate improve-
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higher) ment. Changes of 5-11.
7 have been defined in
literature as being clini-
cally meaningful (Borghs
2012; Cramer 2004;
Wiebe 2002).
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; OR: odds ratio; SUDEP: sudden unexpected death in epilepsy patients; p-y: patient-years; SD: standard deviation
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 More trials and patients are needed to allow more precise estimation of stimulation effects (including more rare adverse effects).
2 The confidence interval includes clinically non-significant changes, however, the observed trend for increasing efficacy over time
probably underestimates the treatment effect.
4 One subject experienced a spectacular seizure frequency increase after initiation of stimulation, which was reversible after lowering
output voltage. New or worse seizures occurred more frequently in the stimulation group compared to the control group but differences
did not reach statistical significance.
5 Although clinically meaningful differences in formal neuropsychological testing results seem unlikely on the group level, the discrepancy
between objective and subjective measures needs further clarification.
7
D
e
e
p
b
ra
in
a
n
d
c
o
rtic
a
l
stim
u
la
tio
n
fo
r
e
p
ile
p
sy
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
4
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
B A C K G R O U N D
Description of the condition
Epilepsy is a common neurological disorder affecting 0.5% to 1%
of the population (Forsgren 2005). More than 30% of all epilepsy
patients suffer from uncontrolled seizures or have unacceptable
medication-related side effects (Kwan and Brodie 2000). Alter-
native treatment options are available for patients with refractory
seizures. Addition of newly developed antiepileptic drugs to the
treatment regime may result in freedom from seizures in this pop-
ulation group. However, the chance of becoming seizure-free with
this strategy is limited and estimated to be around 6% when com-
pared to placebo (Beyenburg 2009). Surgery for epilepsy leads to
long-term freedom from seizures in approximately 58%of suitable
surgery candidates (Engel 2003). For the remainder, few options
are left and neurostimulationmay provide an alternative treatment
(Engel 2003).
Description of the intervention
Both extracranial (vagus nerve stimulation) and intracranial (deep
brain stimulation (DBS) and cortical (neocortex and cerebellar
cortex) stimulation) neurostimulation have been used as treat-
ments for epilepsy (Boon 2007a). Intracranial stimulation is the
direct application of an electrical current to central nervous sys-
tem structures by means of implanted (DBS) or subdural (cortical
stimulation) electrodes connected to an implantable pulse gener-
ator.
How the intervention might work
The precise mechanism of action of DBS still needs to be eluci-
dated. Several mechanisms of action have been proposed. By con-
tinuous application of current via the electrodes, the targeted brain
structures may be (functionally) inhibited. This is done in a re-
versible manner since the stimulation can be stopped at any time.
The effect of the inhibition depends on the targeted structures,
thus depending on the location of the implanted electrodes in the
brain. Stimulation of electrodes placed in the epileptic onset re-
gion (for example the hippocampus) may lead to ’local’ inhibition
of the hyperexcitable region and to seizure suppression. Stimula-
tion of electrodes placed in key structures responsible for seizure
propagation (for example the thalamus) may additionally lead to
suppression of seizure spread, based on the connections between
the area of stimulation and other parts of the central nervous sys-
tem. This may provide a likely hypothesis when crucial structures
in the epileptogenic networks are involved (Boon 2007a).
Why it is important to do this review
For both deep brain and cortical stimulation, several uncontrolled
and unblinded trials with discongruent results and high risk of
bias exist. Randomized controlled trials have been performed but
not systematically reviewed. Until now, no clear descriptions of
the outcomes and side effects have been available. The aim of this
systematic review is to give an overview of the current evidence for
the use ofDBS and cortical stimulation as treatments for refractory
epilepsy.
O B J E C T I V E S
To assess the efficacy, safety and tolerability of deep brain and
cortical stimulation for refractory epilepsy based on randomized
controlled trials.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs) investigating deep brain or
cortical stimulation in patients with refractory epilepsy were se-
lected. Blinded as well as unblinded studies were considered for
inclusion in this review.
Types of participants
Patients with refractory epilepsy with partial or generalized
seizures, or both. Partial seizures are found in a localization-related
form of epilepsy in which seizure semiology or findings from in-
vestigations disclose a localized origin of the seizures. With gen-
eralized seizures the first clinical changes indicate involvement of
both hemispheres (ILAE classification). Patients are considered to
be refractory if they suffer from uncontrolled seizures despite ade-
quate treatment with at least two first-line antiepileptic drugs (ei-
ther as monotherapy or in combination) that are appropriate for
the epileptic syndrome, or they experience unacceptable medica-
tion-related side effects. In adults, at least two years of treatment
is recommended before drug-resistant epilepsy can be diagnosed
(Kwan 2010; Kwan and Brodie 2009).
Both patients with normal and abnormal magnetic resonance
imaging (MRI) were included. Patients who had undergone
other treatments besides antiepileptic drugs (for example resective
surgery or vagus nerve stimulation) were also included.
8Deep brain and cortical stimulation for epilepsy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Types of interventions
Deep brain stimulation (DBS) (in different intracranial regions)
or cortical (neocortex or cerebellar cortex) stimulation. Both treat-
ments could have been compared to a control patient group: 1)
receiving sham stimulation, 2) undergoing resective surgery, or 3)
being further treated with antiepileptic drugs, depending on the
study protocol.
Types of outcome measures
Primary outcomes
(1) Seizure freedom: the proportion of participants that was free of
seizures (complete absence of seizures, comparable with Engel clas-
sification class I (Jehi 2008)) during the randomized period, i.e. the
phase of the trial during which, according to treatment allocation,
one group of patients received the intracranial neurostimulation
treatment and the other group the control treatment (in contrast
to open-label follow-up periods of the same trials during which
(nearly) all patients received the neurostimulation treatment un-
der investigation in an unblinded manner, without any control
group). For RCTs with longer randomized phases, subanalyses per
three-month epochs were performed (e.g. months one to three,
months four to six).
(2) Responder rate: proportion of patients with at least a 50%
seizure frequency reduction, compared to the baseline period,
throughout the randomized period.
Secondary outcomes
(1) Seizure frequency reduction: percentage reduction in seizure
frequency during the randomized phase of the trial compared to
baseline. When the needed data were not presented in the respec-
tive article, they were calculated (if raw data were present) or the
authors were contacted.When necessary to avoid treatment effects
> 100%, we directly compared ’on’ to ’off ’ stimulation periods
instead of referring to baseline seizure frequency (as for Van Buren
1978, see also Appendix 1).
(2) Adverse events: adverse events occurring throughout the ran-
domized period including surgery-related and device-related ad-
verse events.
(3) Neuropsychological testing: results of neuropsychological test-
ing during or at the end of the randomized period.
(4) Quality of life: results of questionnaires concerning quality of
life that were completed during or at the end of the randomized
period.
Search methods for identification of studies
Electronic searches
We searched the following electronic databases, without any lan-
guage restrictions:
(1) PubMed (6 August 2013), using the search strategy outlined
in Appendix 2;
(2) the Cochrane Epilepsy Group Specialized Register (31 August
2013), which was searched by Alison Beamond andGrahamChan
using the search strategy outlined in Appendix 2; and
(3) the Cochrane Central Register of Controlled Trials (CEN-
TRAL) (The Cochrane Library 2013, Issue 7), using the search
strategy outlined in Appendix 2.
Searching other resources
We reviewed the reference lists of retrieved studies to search for
additional reports of relevant studies.
We contacted authors of relevant trials identified by our search,
other researchers in the field, and manufacturers of the devices to
identify unpublished or ongoing studies, or studies published in
non-English journals.
Data collection and analysis
Selection of studies
Four review authors (Mathieu Sprengers (MS), Kristl Vonck (KV),
EvelienCarrette (EC) and Paul Boon (PB)) independently assessed
the identified trials for inclusion. Any disagreements were solved
by discussion and by involving another review author (Anthony
Marson (AM)).
Data extraction and management
Relevant data were extracted into a prespecified data extraction
form by two review authors (MS and KV). If additional data were
needed, the investigators of the studies were contacted. Disagree-
ments were solved by discussion.
The following data were extracted.
(1) Methodological and trial design:
(a) method of randomization and sequence generation;
(b) method of allocation concealment;
(c) blinding methods (patient, physician, outcome assessor);
(d) information about sponsoring;
(e) whether any participants had been excluded from reported
analyses;
(f ) duration of period between implantation and start of the treat-
ment period;
(g) duration of treatment period and, in the case of a cross-over
design, washout period;
(h) antiepileptic drug (AED) policy.
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(2) Participants and demographic information:
(a) number of participants allocated to each treatment group;
(b) age and sex;
(c) information about type of epilepsy and seizures types;
(d) duration of epilepsy;
(e) additional information if applicable and available (intellectual
capacities, neuroimaging results).
(3) Intervention:
(a) stimulation target;
(b) output voltage and current;
(c) stimulation frequency;
(d) pulse width;
(e) continuous, intermittent or responsive (’closed-loop’) stimula-
tion.
(4) Outcomes:
(a) seizure freedom;
(b) responder rate;
(c) seizure frequency reduction;
(d) adverse events;
(e) neuropsychological outcome;
(f ) quality of life.
Assessment of risk of bias in included studies
Themethodological quality of the studies was independently eval-
uated by two review authors (MS and KV) according to the guide-
lines in the Cochrane Handbook for Systematic Reviews of Interven-
tions (Higgins 2011).
• The risk of bias was assessed for each individual study using
the Cochrane Collaboration’s tool for assessing risk of bias.
• Randomization: only RCTs were included in this review.
Studies with inadequate methods of allocation concealment were
planned to be excluded.
• Blinding of participants, personnel and outcome assessors:
double-blind studies were preferred but single-blind and even
unblinded (comparison to resective surgery or antiepileptic
drugs) studies were also eligible for inclusion in the review.
• Incomplete outcome data: this was evaluated separately for
each study. Studies where losses to follow-up differed
significantly between the treatment and control groups were
planned to be excluded.
• Selective reporting: this was evaluated separately for each
study (selective outcome reporting) and, furthermore, if
sufficient studies were identified we planned to explore if there
was any evidence of publication bias using funnel plots.
Several studies have reported results thatmay be consistent with an
outlasting effect after intracranial stimulation (Andrade 2006; Lim
2007;McLachlan 2010; Velasco 2007). Such an effect could mask
or reduce any treatment effect if seizure frequency in the control
group is evaluated after previous stimulation without an adequate
washout period. As there is no general consensus concerning this
outlasting effect, we judged the risk of bias in such studies as
’uncertain’, whereas studies without prior stimulation or with an
adequate washout period were classified as ’at low risk of bias’.
Finally, we also made judgements if antiepileptic drugs were
changed during the trial as this could also influence observed treat-
ment effects.
Measures of treatment effect
We planned to express results of categorical outcomes as relative
risks (RR) with 95% confidence intervals (CI). However, to com-
bine results from parallel group (unpaired data) and cross-over tri-
als (paired data) we used the method described by Curtin 2002,
Elbourne 2002 and Stedman 2011. This method makes use of
maximum likelihood estimate odds ratios (OR) (Mantel-Haenszel
ORs) for parallel trials and marginal Becker-Balagtas ORs (Becker
1993) for cross-over trials. Treatment effects of continuous out-
comes were expressed as mean differences with 95% CIs.
Unit of analysis issues
Results from cross-over trials were analysed and incorporated in
the meta-analysis as paired data, using the approach proposed by
Curtin 2002.
Dealing with missing data
Where data for our chosen outcomes were not provided in trial
reports, the original investigators were contacted and further data
were requested. If raw data were available, missing outcomes were
calculated, if possible (for example seizure frequency reduction).
Assessment of heterogeneity
Clinical heterogeneity was assessed by comparing the clinical and
trial characteristics and a judgementwasmade as towhether signif-
icant clinical heterogeneity was present. Statistical inconsistency
was assessed by visual inspection of the forest plots and by using
the I² statistic and the Chi² test (Q test).
Data synthesis
If neither clinical nor statistical heterogeneity were found, results
were pooled using a fixed-effect model. We planned to use the
Mantel-Haenszel method for dichotomous outcomes and the in-
verse variancemethod for continuous outcomes.However, to com-
bine data from parallel and cross-over trials we had to use the
generic inverse variance method. This approach also allowed in-
corporation of treatment effects estimated by regression and other
models. As none of the cross-over trials evaluated the effect of
stimulation on quality of life, we used the inverse variance method
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for this continuous outcome. Although quality of life was evalu-
ated using the QOLIE-89 or QOLIE-31 (abbreviated version of
QOLIE-89) questionnaires in different trials, we chose the mean
difference (MD) approach instead of the standardized mean dif-
ference (SMD) approach. Firstly, both questionnaires have the
same range and very similar means, standard deviations and min-
imally clinically important change values in the same population
(Cramer 1998; Devinsky 1995;Wiebe 2002). Second, we thought
the MD approach would introduce less error then the SMD ap-
proach, which attributes differences in standard deviations entirely
to differences in measurement scales and ignores real differences
in variability among study populations. Finally, unlike the SMD
approach, theMD approach allows us to combine final values and
change scores. In view of the difficulty in combining neuropsy-
chological data from various studies, we summarized the data for
this outcome only qualitatively in the text. The same was true for
adverse events, due to their diverse nature.
Subgroup analysis and investigation of heterogeneity
As stimulation of different intracranial structures may not be
equally effective, and lead to different adverse events, results were
not pooled across different targets but were presented per individ-
ual target for reasons of clinical heterogeneity.
Sensitivity analysis
If sufficient studies were found, we planned to assess the effect
of study quality on the outcome. Because we initially planned to
express results of categorical outcomes as RR instead of OR, we
also performed a sensitivity analysis using RR as described by Zou
2007. Furthermore, if different strategies could be followed we
planned to analyse their consequences in a sensitivity analysis.
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification;
Characteristics of ongoing studies.
Results of the search
See Figure 1 for a flow-diagrammatic summary of the search re-
sults. Eighty-eight articles were identified as potentially eligible
for inclusion in this review. Sixty-three articles were excluded as
they did not meet the eligibility criteria: 53 were not RCTs, eight
assessed intracranial stimulation for other purposes (or in another
population) than refractory epilepsy, and in two articles the effi-
cacy of another intervention (transcranial direct current stimula-
tion) was evaluated.
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Figure 1. Study flow diagram.
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Four records described three recent studies. One is still recruiting
patients (Boon 2007b: hippocampal stimulation), two others have
been preliminarily terminated (Chabardes 2005: subthalamic nu-
cleus stimulation; Wiebe 2008: hippocampal stimulation). When
the results of the latter are not published, the authors will be con-
tacted and asked to provide their partial results.
Four records mentioned an RCT evaluating the efficacy and safety
of DBS of the mammillary bodies and mammillothalamic tracts
(van Rijckevorsel 2004). However, up to now the results have not
been published. The authors were contacted but have not provided
data yet. Further efforts to acquire these data will be undertaken
by the first update of this review. Another record is a recently
published congress abstract of a single-blindwithin-subject control
study of centromedian thalamic DBS (Valentin 2012). Upon a
more detailed full-text article publication, eligibility for inclusion
in this review will be assessed.
Sixteen articles describing 10 studies fulfilled the criteria for inclu-
sion in this review. As the results of one of these studies (Velasco
2000) were only presented in a graph (no exact figures), only nine
studies were included in the quantitative synthesis (meta-analysis).
Description of the included studies
See: Characteristics of included studies.
Nine out of 10 included studies evaluated the safety and efficacy
of open-loop (scheduled) stimulation, the remaining studies con-
cerned closed-loop (responsive) stimulation. Stimulation of the
ictal onset zone (including the hippocampus (three studies) and
the trial about responsive stimulation) as well as of more remote
network structures has been studied. The latter included the cere-
bellar cortex (three studies) and the anterior (one study) and cen-
tromedian (two studies) thalamic nucleus.
1. Anterior thalamic nucleus stimulation
Fisher 2010, also known as the SANTE trial, is a parallel group
RCT evaluating the efficacy and safety of bilateral anterior thala-
mic nucleus DBS in 109 patients (age 18 to 65 years) with refrac-
tory partial-onset epilepsy (mean duration of epilepsy: 22.3 years,
median baseline seizure frequency: 19.5 per month). After one
month of postoperative recovery, patients entered a three-month
blinded randomized phase during which half of the participants
received stimulation and half did not. This was followed by a nine-
month open-label period during which all patients received stim-
ulation in an unblinded way and stimulation parameters could be
programmed on an individual basis but antiepileptic drugs (AED)
were still kept constant. From the 13th month on, AEDs could
vary freely (’long-term follow-up’). All outcomes considered for
this review were examined.
2. Centromedian thalamic nucleus stimulation
1. Fisher 1992 was a cross-over randomized trial in seven patients
(age 16 to 41 years) who were found to be poor candidates for
epilepsy surgery, two of them having (multi)focal epilepsy and
five generalized epilepsy (2/5 had Lennox-Gestaut syndrome). The
patients had been suffering from epilepsy for 14 to 29 years and
had a mean monthly baseline seizure frequency of 23.4 seizures.
Patients were randomized one to two months postoperatively to
first receive either bilateral centromedian thalamic nucleus (two
hours per day) or sham stimulation. The two treatment blocks
lasted three months with a three-month washout phase between
them. After this nine-month randomized and blinded period, all
patients were stimulated during the long-term open-label follow-
up period. All outcomes considered for this review were studied
and reported except for quality of life.
2. Velasco 2000 was a cross-over randomized trial in 13 patients
(age 4 to 31 years) with refractory epilepsy for 4 to 33 years (8
with Lennox-Gestaut syndrome and 5 with localization-related
epilepsy) and a median baseline seizure frequency of 119 seizures
per month. After six to nine months of stimulation in all par-
ticipants, patients entered a six-month randomized double-blind
cross-over protocol. In half of the patients the stimulator was
turned off for threemonths, betweenmonth six andnine, the other
half underwent the same manoeuvre nine to 12 months postoper-
atively. Between month 13 and 15 stimulation was restarted in all
patients in an unblinded manner. Two of the original 15 patients
were explanted before initiation of the randomized double-blind
period due to skin erosions. Seizure frequency during the blinded
three-month period without stimulation was presented in a graph
and compared to the preceding three months (with stimulation).
As these three months only coincided with the three-month stim-
ulation ’on’ period of the double-blind protocol in half of patients,
and furthermore no exact figures were provided, this study could
not be included in the meta-analysis but only in the qualitative
synthesis.
3. Cerebellar stimulation
1. Van Buren 1978 reported their results of cerebellar stimulation
(superior surface of the cerebellumparallel to and about 1 cm from
either side of the midline) in five patients (age 18 to 34 years) with
refractory epilepsy for 8 to 23 years, with a mean baseline seizure
frequency of 5.1 seizures per day. Presumably four had (multi)focal
epilepsy and one had generalized epilepsy. Stimulation was initi-
ated as soon as preoperative seizure frequency had resumed after
electrode implantation. Over the ensuing 15 to 21 months, pa-
tients were hospitalized three or four times for four to six weeks.
During these admissions, seizure frequency was evaluated with
and without stimulation. This was performed in a blinded as well
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as an unblinded way. For this review, only the double-blind data
were considered (in total 26 days ’on’ and 26 days ’off ’). As four
out of five patients’ seizure frequency increased during the trial
(with as well as without stimulation), we decided to directly com-
pare seizure frequency during the stimulation ’on’ and ’off ’ peri-
ods to avoid treatment effects with > 100% reductions in seizure
frequency (see Appendix 1). The analysis expressing treatment ef-
fects with regard to baseline seizure frequency was performed as a
sensitivity analysis.
2. Wright 1984 was a cross-over randomized trial in 12 patients
(age 20 to 38 years) who had had epilepsy for 10 to 32 years. Five
patients had only generalized seizures, one only partial seizures,
four partial and generalized seizures, and in two patients seizures
were difficult to classify (complex partial seizures versus complex
absences). The type of epilepsy was not reported. The six-month
randomized phase started several months after electrode implan-
tation, after the patient had returned to his preoperative seizure
frequency, and consisted of three two-month periods: continuous,
contingent (that is patients received only stimulation when the
’seizure button’ was depressed (during an aura or seizure) and for
two minutes after it was released) and sham stimulation of the
upper surface of the cerebellum (electrodes ± 2 cm parasagittally
from themidline). As there was no baseline period, the sham stim-
ulation period seizure frequency (mean: 62 seizures per month)
served as reference data for the meta-analysis. Apart from quality
of life, all outcomes considered for this review were evaluated.
3. Velasco 2005 studied the efficacy and safety of bilateral stimula-
tion of the superomedial surface of the cerebellum in five patients
(age 16 to 35 years) with generalized (n = 3) or (multi)focal frontal
lobe epilepsy (n = 2) for 11 to 27 years (mean baseline seizure
frequency: 14.1 seizures per month). All patients had generalized
tonic-clonic seizures and 4/5 had tonic seizures. The three-month
parallel-group randomized phase was initiated one month after
electrode implantation and was followed by unblinded stimula-
tion in all patients for 21 months. Seizure frequency and adverse
events were evaluated.
4. Hippocampal stimulation
1. Tellez-Zenteno 2006 was a multiple cross-over RCT in four
patients (age 24 to 37 years) with refractory left medial tempo-
ral lobe epilepsy with mesial temporal sclerosis on MRI whose
risk of postoperative memory deficits prevented resective surgery.
Duration of epilepsy ranged from 16 to 24 years and the mean
monthly baseline seizure frequency was between two and four in
three participants and25 in another. Left hippocampal stimulation
was compared to sham stimulation in three two-month treatment
pairs, each containing one month with and one month without
stimulation. All outcomes considered for this review were studied.
With regards to quality of life, see Appendix 3.
2. Velasco 2007 reported their results of uni- or bilateral hip-
pocampal stimulation (according to seizure focus) in nine patients
(age 14 to 43 years) with intractable temporal lobe epilepsy for
3 to 37 years (mean baseline seizure frequency: 37.9 seizures per
month) who were poor surgery candidates. Five had a normal
MRI and four had hippocampal sclerosis. Seizure frequency and
adverse events were assessed in a double-blind manner during the
first postoperative month during which half of the participants
received stimulation and half did not. After this randomized one-
month period stimulation was turned ’on’ in all patients (follow-
up: 18 to 84 months).
3. McLachlan 2010 was another study evaluating hippocampal
stimulation as a treatment for medically intractable epilepsy in
two patients (age 45 to 54 years) with independent bitemporal
originating seizures for 15 to 29 years (with 32 and 16 seizures per
month, respectively).MRIwas normal in one and showed bilateral
hippocampal sclerosis in the other patient. A three-month post-
operative baseline period was followed by a cross-over protocol
which contained three months of bilateral hippocampal stimula-
tion followed by a three-month washout period and three months
of sham stimulation (control). All outcomes considered for this
review were evaluated except for quality of life.
5. Closed-loop ictal onset zone stimulation
Morrell 2011, also known as the Neuropace study, was a parallel-
group RCT in 191 patients (age 18 to 66 years) with intractable
partial onset seizures for 2 to 57 years with one (45%) or two
(55%) seizure foci. The mean daily baseline seizure frequency was
1.2. After a 12-week baseline period, one or two recording and
stimulating depth or subdural cortical strip leads, or both, were
surgically placed in the brain according to the seizure focus or
foci. A four-week postoperative stabilization period (neurostimu-
lator programmed to sense and record the electrocorticogram; all
patients) and a four-week stimulation optimization period (opti-
mization of stimulation parameters; only patients randomized to
treatment group) preceded the 12-week blinded evaluation period
(BEP) during which, in half of the participants, the seizure focus
was stimulated in response to epileptiform electrographic events.
This was followed by an open-label evaluation period with stimu-
lation ’on’ in all patients. All outcomes considered for this review
were evaluated in this trial.
Risk of bias in included studies
Detailed assessments of each risk of bias item for each included
study can be found in the risk of bias tables in the section
’Characteristics of included studies’. A summary of the review au-
thors’ judgements is shown in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Methods for random sequence generation and treatment alloca-
tion concealment (selection bias) were often poorly described in
the published articles. After personal communication with the au-
thors, however, these were found to be adequate in all trials for
which such additional information could be obtained. As some
authors could not be contacted or provide any further explanation,
there remained some uncertainty about two trials (Tellez-Zenteno
2006; Wright 1984).
Blinding
All 10 trials were reported to be double-blind RCTs. However,
only for eight out of 10 trials the blinding of patients, personnel
and outcome assessors was assessed as adequate. Some uncertainty
remained with regards to Van Buren 1978. For this RCT (which
contained both double-blind and unblinded evaluation periods,
see above) it was not reported whether neuropsychological test-
ing was performed during the blinded or unblinded evaluation
period and if the sealed notes containing the treatment code for
the double-blind evaluation period were double-opaque and by
whom they were handled (for more details: see Characteristics
of included studies). Finally, although the double-blinding pro-
cedure in Velasco 2000 seemed adequate, the authors compared
seizure frequency between stimulation ’off ’ periods (blinded) and
the three-month periods preceding these. Only in about 50% of
participants these latter periods coincided with blinded stimula-
tion ’on’ periods. For the other half, these three months corre-
sponded to unblinded stimulation ’on’ periods, which could have
resulted in performance or detection bias (the seizure frequency
during blinded stimulation ’on’ periods could not be obtained
from the authors).
Morrell 2011 was the sole study where patients were asked at the
end of the BEP if they knew or could guess if they had received
’real’ or sham stimulation.Thiswas of particular importance in this
trial as stimulation parameters were determined individually after
randomization and only in patients allocated to the stimulation
group (for more details: see Characteristics of included studies).
Incomplete outcome data
Risk of bias arising from incomplete outcome data was assessed as
high for Fisher 1992 only. In this study one of the two patients
who improved noticeably with stimulation experienced a marked
seizure frequency increase in the washout period and, therefore,
was dropped from the blinded protocol whereafter stimulation
was successfully reinstalled. As there were only seven patients (two
responders) this one patient represented a significant proportion,
especially when taking into consideration the reason for dropout
and the fact that a paired analysis of outcome data did not allow
inclusion of this patient in the (default) meta-analysis.
Selective reporting
Evidence suggesting selective reporting was present for a number
of trials. Statistical analysis included only a subgroup of patients in
Fisher 1992 (only patients with generalized tonic-clonic seizures,
not prespecified in the ’Methods’ section) or a subset of available
data in McLachlan 2010 (median monthly seizure frequency in-
stead of total number of seizures). As raw data were published in
the original articles or provided upon our request, this had no in-
fluence on the review.
Fisher 2010 did not report on or mention all available outcome
measures in the published paper (for example seizure-free days and
seizure-free intervals) but only reported that ’changes in additional
outcome measures did not show significant differences’. Again,
this had no direct consequences for this review as these outcome
variables were not taken into consideration.
In various trials results were incompletely reported, however with-
out strong evidence of selective reporting.
• Seizure frequency reduction in Velasco 2000 and Velasco
2007 was only presented in graphs. As exact figures could only
be provided by Velasco 2007, this prevented inclusion of Velasco
2000 in our meta-analysis.
• Neuropsychological testing results were often only reported
to be non-significant (Fisher 1992; Wright 1984) or were
incompletely published (Tellez-Zenteno 2006). However, as: 1)
neuropsychological testing yields too abundant data for
publication in a journal article (and therefore not entirely
reporting them does not necessarily reflect study quality), and 2)
we did not attempt to incorporate these results into a meta-
analysis but rather described them in a qualitative way; we think
this is of less concern for this review.
• Finally, as not all exact figures with regards to adverse
events, neuropsychological outcome and quality of life could be
reported in Morrell 2011 (too much data), the authors provided
us with these data.
Outlasting effect after prior stimulation
Four trials with a parallel-group design (Fisher 2010; Morrell
2011; Velasco 2005; Velasco 2007) and two cross-over trials with a
three-monthwashout period (Fisher 1992;McLachlan 2010)were
judged as being at low risk of bias. Two cross-over trials (Tellez-
Zenteno 2006;Wright 1984) did not contain any washout period,
which couldmask or reduce any treatment effect if stimulation had
an outlasting effect. This was even more true for Van Buren 1978
and Velasco 2000, two cross-over trials for which the randomized
16Deep brain and cortical stimulation for epilepsy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
evaluation took place only after 6 to 21 months of stimulation,
without any washout period.
Antiepileptic drug (AED) policy
The antiepileptic drug regimenwas kept unchanged in all trials but
Tellez-Zenteno 2006, in which it was changed in three out of four
patients during the trial. Morrell 2011 allowed benzodiazepines
for seizure clusters or prolonged seizures but it was unlikely this
significantly influenced the reported results.
Effects of interventions
See: Summary of findings for the main comparison
Anterior thalamic nucleus stimulation; Summary of findings
2 Centromedian thalamic nucleus stimulation; Summary of
findings 3 Cerebellar stimulation; Summary of findings 4
Hippocampal stimulation; Summary of findings 5 Responsive
ictal onset zone stimulation
See: Figure 3; Figure 4; Figure 5; Figure 6.
Figure 3. Forest plot of comparison: 1 Stimulation versus sham stimulation, outcome: 1.1 Seizure freedom.
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Figure 4. Forest plot of comparison: 1 Stimulation versus sham stimulation, outcome: 1.2 Responder rate.
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Figure 5. Forest plot of comparison: 1 Stimulation versus sham stimulation, outcome: 1.3 Seizure
frequency reduction.Note: Fisher 2010 (anterior thalamic nucleus stimulation) and Morrell 2011 (closed-loop
ictal onset zone stimulation) estimated the treatment effect and its standard error on a logarithmic scale,
using the generalized estimating equation (GEE) model. As in this figure standard errors could not be inputted
on the logarithmic scale, the values for the 95% confidence interval presented here differ slightly from the
(more correct) values mentioned in the text. These correct values are -17.4% with 95% CI [-31.2;-1.0] for
Fisher 2010 and -24.9% with 95% CI [-40.1;-6.0] for Morrell 2011.
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Figure 6. Forest plot of comparison: 1 Stimulation versus sham stimulation, outcome: 1.4 Quality of Life. To
measure quality of life, Tellez-Zenteno 2006 and Morrell 2006 used the QOLIE-89 questionnaire, whereas
Fisher 2010 used the QOLIE-31 questionnaire (= abbreviated form of the QOLIE-89 questionnaire). As both
questionnaires have the same range and very similar means, standard deviations and minimum clinically
important change values in the same population (Cramer 1998; Devinsky 1995; Wiebe 2002), results from the
different trials are nevertheless presented in one forest plot. Improvements of 5-11.7 have been defined in the
literature (Borghs 2012; Cramer 2004; Wiebe 2002) as being clinically meaningful, positive is better.
1. Anterior thalamic nucleus stimulation
a. Seizure freedom
During the three-month blinded randomized phase of Fisher 2010
1/55 patients in the control group was seizure-free versus 0/54 in
the stimulated group (OR 0.33; 95% CI 0.01 to 8.36).
b. Responder rate
Responder rate was not significantly different in the stimulated
(29.6%) compared to the control (25.9%) group (OR 1.20; 95%
CI 0.52 to 2.80).
c. Seizure frequency reduction
Over the entire blinded randomized period anterior thalamic nu-
cleus stimulation resulted in a significantly (-17.4%; 95% CI -
31.2 to -1.0) higher seizure frequency reduction compared to sham
stimulation. The authors reported a trend for increasing differ-
ences in median monthly seizure frequency reduction over time
between the groups (stimulation versus control: month 1: -33.9%
versus -25.3%, month 2: -42.1% versus -28.7% and month 3: -
40.4% versus -14.5%; the adjusted treatment effects being -10%
(P = 0.37), -11% (P = 0.34) and -29% (P = 0.002) respectively).
d. Adverse events
During the BEP, two self-reported adverse events occurred signif-
icantly more frequently in the stimulated group compared to the
control group: depression (14.8% versus 1.8%; P = 0.02, Fisher’s
Exact Test) and subjectivememory impairment (13.0 versus 1.8%;
P = 0.03). On the contrary, there were significantly fewer epilepsy-
related injuries (7.4% versus 25.5%; P = 0.01). Differences for
other adverse events were not statistically significant and included:
confusional state (7.4% versus 0.0%; P = 0.06), anxiety (9.3%
versus 1.8%; P = 0.11), paraesthesia (9.3% versus 3.6%; P = 0.27),
new or worse partial seizures with secondary generalization (9.3%
versus 5.5%; P = 0.48) and new or worse simple (5.6% versus
1.8%; P = 0.36) or complex (9.3% versus 7.3%; P=0.74) partial
seizures. One patient experienced 210 complex partial seizures in
the three days after turning on the stimulator (baseline seizure fre-
quency of 19 seizures per month), resolving with reprogramming
of the stimulator.
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Over the entire study period, five asymptomatic haemorrhage
events were reported (four after the initial implant procedure, one
following a seizure and a fall and remote from the lead tract). All
were asymptomatic. Fourteen participants (12.7%) developed im-
plant site infections, either in the stimulator pocket (7.3%), the
lead extension tract (5.5%) or at the site of the burr hole (1.8%).
There were no parenchymal brain infections. In nine patients this
eventually led to (temporary) hardware removal. Leads initially
implanted outside the target structure had to be replaced in 8.2%
of participants. Implant site pain was reported by 10.9% of par-
ticipants during the first year of the trial. Five participants experi-
enced status epilepticus during the trial, two of them with stim-
ulation ’on’: one during month two of the blinded phase (com-
plex partial status) and one when the stimulator was turned ’on’
after the blinded phase (complex partial status, resolving within
five days after switching stimulation ’off ’). Five participants died
during the course of the trial but none of the deaths were judged
as device-related. Mortality causes were: SUDEP (n = 2 + 1 be-
fore device implantation), and drowning and suicide (probably in
relation to recent life events). The SUDEP rate during stimula-
tion (2 SUDEPs over 325 patient-years with stimulation = 6.2 per
1000 patient-years) fell within the range reported in comparable
refractory epilepsy populations (2.2 to 10 per 1000 patient-years)
(Tellez-Zenteno 2005; Tomson 2008).
e. Neuropsychological outcome
Although self-reported depression and subjective memory impair-
ment occurred significantly more frequently in the stimulated
group (see above), changes in neuropsychological test scores for
cognition andmoodwere very similar in the treatment and control
groups and were not significantly different. The evaluated items
can be found in Characteristics of included studies. Looking at
the individual patients, worsening (> 1 standard deviation change
(SD)) of Profile of Mood States Depression subscale (POMS-D)
was present in 3/8 stimulated participants with self-reported de-
pression. None of the seven patients with subjective memory im-
pairment showed worsening (> 1 SD) of verbal or visual memory
scores.
f. Quality of life
Changes from baseline in overall QOLIE-31 scores were compa-
rable for the treatment (+ 2.5) and control (+ 2.8) group. TheMD
in change score (-0.30) was neither statistically (95% CI -3.50 to
2.90) nor clinically significant (positive is better, improvements of
5 to 11.7 have been defined in the literature (Borghs 2012; Cramer
2004; Wiebe 2002) as being clinically meaningful).
2. Centromedian thalamic nucleus stimulation
a. Seizure freedom
None of the patients in the Fisher 1992 trial (two hours of in-
termittent stimulation per day) achieved seizure freedom, neither
with nor without stimulation (OR 1.00; 95% CI 0.11 to 9.39).
Although one patient was completely seizure-free at themaximum
open-label follow-up (minimum follow-up of one year, mean 41.2
months), Velasco 2000 (24 hours of intermittent stimulation per
day) did not report on differences in seizure freedom between
stimulation ’on’ versus ’off ’ periods in the double-blind protocol
performed betweenmonth six andmonth 12 of the trial. However,
as mean seizure frequency reductions were very similar in both
groups, major differences in seizure freedom seem unlikely.
b. Responder rate
Statistically significant differences in responder rate, favouring ei-
ther the stimulation or the control group, could not be demon-
strated by Fisher 1992 (OR 1.00; 95% CI 0.27 to 3.69). Two
patients did experience ≥ 50% seizure frequency reductions with
stimulation ’on’ compared to baseline, but one of them had a sim-
ilar reduction without stimulation and the other could not be in-
cluded in a paired analysis as he was dropped from the blinded
protocol due to a seizure frequency increase during the washout
period (see also ’Sensitivity analyses’).
Eleven out of 13 patients showed ≥ 50% seizure reductions at
maximum follow-up in Velasco 2000, but again the authors did
not report on differences in responder rates between stimulation
’on’ versus ’off ’ periods. As for seizure freedom, however, impor-
tant differences in responder rate were improbable as mean seizure
frequency reductions were comparable for stimulation ’on’ and
’off ’ periods.
c. Seizure frequency reduction
Paired analysis (thus excluding one patient) revealed a non-sig-
nificant 7.1% seizure frequency increase during stimulation ’on’
compared to stimulation ’off ’ periods in Fisher 1992 (95% CI -
44.1 to 58.2). Successive months of stimulation were not associ-
ated with a clear trend for increasing efficacy over time during the
three-month stimulation ’on’ period.
Velasco 2000 found very similar and statistically not significantly
different reductions in seizure frequency during stimulation ’off ’
periods in the double-blind phase of the trial and the three-month
period preceding it (with stimulation ’on’). Graphs showed ap-
proximately a mean 75% reduction in total seizure frequency dur-
ing stimulation ’on’ as well as stimulation ’off ’ periods (P = 0.23).
Some open-label trials have reported that complex partial seizures
may be less prone to centromedian thalamic nucleus stimulation
(Velasco 1993; Velasco 1995). Excluding patients with only com-
plex partial seizures (n = 1) in a subgroup analysis of Fisher 1992
showed a non-significant -8.9% MD in seizure frequency reduc-
tion (95% CI -79.0 to 61.3%). Although, compared to baseline
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seizure frequency, reductions in generalized tonic-clonic seizures
and atypical absences in Velasco 2000 weremore pronounced than
those found for complex partial seizures, very similar reductions
in seizure frequency were found for any seizure type during stimu-
lation ’on’ and ’off ’ periods and statistically significant differences
could not be demonstrated (P values being 0.27, 0.29 and 0.72
respectively).
d. Adverse events
Stimulation-related side effects did not occur in Fisher 1992 or
Velasco 2000. Fisher 1992 explicitly reported that no single pa-
tient had new seizures or worsening of seizures after initiation of
stimulation.
However, various patients in both trials experienced some device-
or procedure-related adverse events. One patient in Fisher 1992
required repair of the connection to the pulse generator on one
side because no stimulation effect was evident at any intensity, ei-
ther behaviorally or by electroencephalogram (EEG) monitoring.
A postimplantation computed tomography (CT) scan in another
patient revealed an asymptomatic and minimal haemorrhage in
the vicinity of one depth electrode. Skin erosion forced explan-
tation in three patients of the Velasco 2000 trial, including two
children (five and six years old) whose stimulators had to be re-
moved before the double-blind protocol took place. Young chil-
dren seemed particularly vulnerable to skin erosions because of the
size of the hardware, which is designed for an adult population.
e. Neuropsychological outcome
Multivariate analysiswith repeatedmeasures showedno significant
differences in any of the neuropsychological tests between baseline
and stimulation ’on’ and ’off ’ periods inFisher 1992.The cognitive
assessment battery can be found in Characteristics of included
studies.
f. Quality of life
None of the two studies evaluated the impact of centromedian
thalamic stimulation on quality of life.
3. Cerebellar stimulation
a. Seizure freedom
Regardless of stimulation status, seizure freedom could not be
achieved in any of the trials evaluating cerebellar stimulation (OR
0.96; 95% CI 0.22 to 4.12).
b. Responder rate
Cerebellar stimulation did not result in a statistically significantly
higher responder rate compared to sham stimulation (OR 2.43;
95% CI 0.46 to 12.84). In the treatment groups, there were 1/
5 (Van Buren 1978), 1/9 (Wright 1984) and 2/3 (Velasco 2005)
responders, whereas sham stimulation was associated with a ≥
50% reduction in seizure frequency in 1/5, 0/9 and 0/2 patients,
respectively.
There were no responders with contingent stimulation in Wright
1984 (OR 1.00; 95% CI 0.12 to 8.64).
c. Seizure frequency reduction
The pooled mean treatment effect was a -12.4% change in seizure
frequency in favour of cerebellar stimulation but this effect did not
reach statistical significance (95% CI -35.3 to 10.6). Only Velasco
2005 reported enough details to evaluate a possible trend for in-
creasing efficacy over successive months of stimulation. Although
the treatment effect was most pronounced in the third month of
stimulation (month 1: -54% versus -29%, month 2: -31% versus
-14%, month 3: -82% versus -14%), the small number of patients
and the observed variability make it premature to draw any con-
clusions on this issue. Finally, Van Buren 1978 stated that no slow
trends toward improvement could be noticed.
Contingent stimulation was not associated with changes in seizure
frequency inWright 1984 (treatment effect +0.9%; 95% CI -23.2
to 24.9%).
d. Adverse events
Stimulation-related side effects were not reported in any of the
trials. Psychiatric evaluation after completion of the Wright 1984
trial did not detect adverse psychiatric sequelae as a result of the
stimulation trial.
In contrast, device- or procedure-related adverse events were not
uncommon. Electrode migration necessitating repeated surgery
occurred in 3/12 and 3/5 patients in Wright 1984 and Velasco
2005 respectively. An electrode lead causing pain needed to be
repositioned in one patient and a receiver pocket that had burst
open had to be resutured in another (Wright 1984). Leakage of
cerebrospinal fluid into the subcutaneous apparatus tracts required
resuturing in 3/5 patients of Van Buren 1978, and Wright 1984
reported that most patients experienced temporary swelling over
one or both receiver sites, presumably due to cerebrospinal fluid ac-
cumulation, but that this spontaneously resolved. A subcutaneous
seroma had to be drained in one of Velasco’s patients. Wound
infections could be settled with antibiotics in two patients but
required total hardware removal in one patient (Velasco 2005;
Wright 1984). Finally, repeated surgery was performed in another
two patients due to a defective receiver and abdominal wound
erosion (Wright 1984). Taken all together, in every trial about half
of the patients required repeated surgery (3/5 in Van Buren 1978,
6/12 in Wright 1984 and 3/5 in Velasco 2005).
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e. Neuropsychological outcome
Each patient inWright 1984 was assessed by a clinical psychologist
in every phase of the trial but ’psychometry’ could not reveal any
major change in any of the patients. More details were provided
by Van Buren 1978. Consistent changes in full scale intelligence
or memory quotients could not be detected, nor were there any
significant changes in subtests (performance and oral intelligence
quotient). Comparing ’on’ to ’off ’ stimulation, the test scores of
the four individuals they evaluated showed very similar results
in two participants, a moderate increase in one patient, and a
moderate decrease in another.
f. Quality of life
None of the trials on cerebellar stimulation formally evaluated im-
pact on quality of life. However, Wright 1984 reported that all his
patients but one felt better for cerebellar stimulation, thought it
had helped them, and wished to continue it after completion of
the trial. However, only five patients chose one phase of the trial
as being different from the others: two singled out the continu-
ous, one the contingent, and two others the no-stimulation phase.
Moreover, only one patient’s subjective impression agreed with the
authors’ assessment and in this patient the no-stimulation period
was his best. Finally, one patient reported a reduction of episodes
of incontinence with contingent but not continuous stimulation,
which beneficially affected his social possibilities.
4. Hippocampal stimulation
a. Seizure freedom
No single patient was seizure-free for the duration of the RCT
they had been included in (OR 1.03; 95% CI 0.21 to 5.15).
b. Responder rate
Hippocampal stimulation was not associated with significantly
higher responder rates compared to sham stimulation (OR 1.20;
95% CI 0.36 to 4.01). There were no responders in McLachlan
2010, 1/4 patient experienced a ≥ 50% reduction in seizure fre-
quency with as well as without stimulation in Tellez-Zenteno
2006, and Velasco 2007 reported 1/4 responder in the treatment
group compared to 0/5 in the control group.
c. Seizure frequency reduction
Hippocampal stimulation significantly reduced seizure frequency
with a pooled mean treatment effect of -28.1% (95% CI -34.1
to -22.2). None of the authors provided enough data to allow
evaluation for trends of increasing efficacy over time.
d. Adverse events
No adverse events occurred in relation to stimulation and there
were no early surgical complications in any of the trials (McLachlan
2010; Tellez-Zenteno 2006; Velasco 2007). However, skin erosion
and local infection 24 months after implantation required explan-
tation in 3/9 patients in Velasco 2007.
e. Neuropsychological outcome
Neuropsychological testing in Tellez-Zenteno 2006 could not re-
veal significant differences between baseline, ’on’ and ’off ’ periods
in any of the formal or subjective measures (see Characteristics of
included studies for the different tests they performed). Moreover,
reported mean scores were exactly or nearly the same for the ’on’
and ’off ’ periods. Of particular interest was a patient who previ-
ously had a right temporal lobectomy and whose memory scores
were not influenced by left hippocampal stimulation. The Center
for Epidemiologic Studies Depression (CES-D) scale could not
demonstrate meaningful changes in mood states during baseline
(19), ’on’ (20) and ’off ’ (18) stimulation periods.
McLachlan 2010 assessed the objective and subjective memory of
their two patients during baseline, ’on’, washout and ’off ’ periods.
They found no changes in one participant and contradictory re-
sults in the other. This latter patient reported improved subjective
memory during the stimulation ’on’ period (baseline second, ’off ’
third to - sixth and ’on’ 12th to 13th percentile (pc), higher was
better) but formal testing pointed towards worsening of verbal
(baseline first, ’off ’ 14th and ’on’ second pc) as well as visuospatial
(baseline 21st, ’off ’ 42nd and ’on’ first pc) memory.
f. Quality of life
Only Tellez-Zenteno 2006 evaluated the impact of hippocampal
DBS on quality of life. Repeated (once per month) testing in three
patients could not demonstrate statistically significant differences
betweenQOLIE-89 scores during baseline (57), ’on’ (55) and ’off ’
(60) periods (treatment effect -5.0; 95% CI -53.3 to 43.3), which
was obviously not surprising given the small number of patients.
This five-point difference was clinically of borderline significance
(positive was better, improvements of 5 to 11.7 have been defined
in the literature (Borghs 2012; Cramer 2004; Wiebe 2002) as
being clinically meaningful).
5. Closed-loop ictal onset zone stimulation
a. Seizure freedom
There were no statistically significant differences in seizures free-
dom during the three-month BEP of Morrell 2011, with 2/97
and 0/94 patients being seizure-free in the treatment and control
group, respectively (OR 4.95; 95% CI 0.23 to 104.44).
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b. Responder rate
With 28.9% of participants experiencing ≥ 50% reductions in
seizure frequency in the treatment group compared to 26.6% in
the group receiving sham stimulation, stimulation status did not
significantly influence responder rates (OR 1.12; 95% CI 0.59 to
2.11).
c. Seizure frequency reduction
Closed-loop stimulation of the ictal onset zone significantly re-
duced seizure frequency, the treatment effect being -24.9% (95%
CI -40.1% to -6.0%). A trend for increasing efficacy over time
could be observed during the three-month BEP, with statistically
significant reductions in seizure frequency from the secondmonth
of stimulation on (treatment versus control group: month 1: -
34.2% versus -25.2% (P = 0.28), month 2: -38.1% versus -17.2%
(P = 0.016) and month 3: -41.5% versus -9.4% (P = 0.008)).
d. Adverse events
There were no significant differences between the treatment and
sham groups in the percentages of patients with mild or serious
adverse events (overall or for any type). In fact, with the exception
of increased complex partial seizures (treatment versus sham: n =
2 versus n = 2), headache (n = 3 versus n = 1) and incision site
infection (n = 2 versus n = 0), each individual type of device-
related (definite or uncertain) adverse event occurred in no more
than one participant in the treatment group. Two participants had
device-related serious adverse events: one patient of the treatment
group and another of the control group had one and three events
related to a change in seizures respectively.
Intracranial haemorrhage occurred in nine participants (4.7%).
The majority of these (7/9) were considered as being serious, but
none of the patients had permanent neurologic sequelae. Six of the
nine events were postoperative: three epidural haematomas, two
intraparenchymal haemorrhages and one subdural haematoma.
The other three events were subdural haematomas attributed to
seizure-related head trauma. Implant or incision site soft tissue
infections occurred in 5.2% and about half of them urged explan-
tation (2.1%). There were no parenchymal brain infections. The
most frequently reported adverse events during the first year of the
trial were related to the cranial implantation of the pulse gener-
ator and included implant site pain (15.7%), headache (10.5%),
procedural headache (9.4%) and dysesthesia (6.3%). Six partici-
pants died over the entire 340 years of patient experience. Causes
were: lymphoma (n = 1), suicide (history of depression, n = 1) and
SUDEP (n = 4, 3 had stimulation enabled). The SUDEP rate (4
SUDEPs over 340 patient-years = 11.8 per 1000 patient-years) was
slightly higher than those usually reported in refractory epilepsy
patients (2.2 to 10 per 1000 patient-years) (Tellez-Zenteno 2005;
Tomson 2008).However, the relatively limited number of patient-
years (in other studies often > 2000 years) made it premature to
draw firm conclusions on this issue. Nevertheless, close monitor-
ing of the SUDEP rate is definitely needed.
e. Neuropsychological outcome
Neuropsychological assessment at the end of the BEP could not
reveal any significant differences between the treatment and sham
groups in any measure. In addition, there were no adverse changes
in mood inventories at the end of the blinded phase of the trial.
The neuropsychological and mood assessment batteries can be
found in Characteristics of included studies. Self-reported depres-
sion occurred in one patient in each group and subjective mem-
ory impairment was reported by one participant belonging to the
treatment group.
f. Quality of life
Changes from baseline in overall QOLIE-89 scores were compara-
ble for the treatment (+2.04) and control (+2.18) groups. TheMD
in change score (-0.14) was neither statistically (95% CI -2.88 to
2.60) nor clinically significant (positive was better, improvements
of 5 to 11.7 have been defined in the literature (Borghs 2012;
Cramer 2004;Wiebe 2002) as being clinically meaningful). These
conclusions applied to the overall as well as any subscale QOLIE-
89 score.
Sensitivity analyses
Expressing treatment effects of dichotomous outcomes as relative
risks (RR) instead of odds ratios (OR) did not change our conclu-
sions. For seizure freedom, effect estimators were nearly identical
however with slightly smaller CIs. With regards to the responder
rate, effect estimators were discretely lower and CIs smaller when
using RR.
Empty cells hindered calculation of odds or risk ratios. In these
situations, it was customary to add +0.5 to each cell (Deeks 2011).
Given the small number of included patients in most trials, we
examined if adding +0.25 instead of +0.5 would change our con-
clusions. In general, this was not the case. Concerning seizure free-
dom, however, CIs were larger (for all targeted structures, for OR
as well as RR) and the treatment effect seemed more pronounced
(but with higher uncertainty) for closed-loop stimulation of the
ictal onset zone (OR 8.91; 95% CI 0.14 to 560). With regards
to the responder rate, treatment effect estimators and CIs were
comparable (except perhaps for a higher degree of uncertainty for
cerebellar stimulation).
Including only trials with a low risk of bias due to an outlasting
effect after prior stimulation (and thus excluding three cross-over
trials without washout periods) did not change our conclusions.
For cerebellar stimulation only one trial remained (Velasco 2005);
and for hippocampal stimulation the following pooled effect esti-
mates were calculated: seizure freedom OR 1.06 (95% CI 0.12 to
9.62), responder rate OR 1.75 (95%CI 0.22 to 14.13) and seizure
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frequency reduction -28.5% (95% CI -34.6 to -22.4). Risks of
other types of bias which could have directly influenced our con-
clusions were mainly present in the three cross-over trials.
As the two participants in McLachlan 2010 experienced very sim-
ilar treatment effects, the standard error associated with the MD
in seizure frequency in this study was the lowest (3.13) among
all trials on hippocampal stimulation. In this way this very small
cross-over study (n = 2) substantially influenced the pooled mean
treatment effect. As its weight in the standard analysis appeared
disproportionally high (94%), we performed a sensitivity analy-
sis using 29.01 (the standard error of Velasco 2007) instead of
3.13 as the standard error for McLachlan 2010. This alternative
analysis yielded a similar -28.2% treatment effect, however with
a higher degree of uncertainty (95% CI -50.7 to -5.8). Excluding
Tellez-Zenteno 2006 (a cross-over trial without washout period)
in this latter analysis resulted in a -45.7% treatment effect for hip-
pocampal stimulation (95% CI -85.9 to -5.5).
To avoid treatment effects > 100%, we directly compared ’on’
and ’off ’ stimulation periods for Van Buren 1978 (see Appendix
1). However, taking baseline seizure frequency as the reference
also for Van Buren 1978 (responder rate OR 2.40; 95% CI 0.21
to 26.82; seizure frequency reduction -123.5%; 95% CI -280.3
to 33.3) did not change our conclusion regarding the efficacy of
cerebellar stimulation (responder rate OR 2.85; 95% CI 0.64 to
12.68; seizure frequency reduction -15.9%; 95% CI -40.3 to 8.5).
Finally, an unpaired analysis of Fisher 1992 (’best case scenario’),
including the patient who seemed to benefit from stimulation
but whose absence of stimulation ’off ’ data (see Characteristics of
included studies) prevented inclusion in a paired analysis, could
not demonstrate a significant responder rate increase (OR 2.00;
95% CI 0.13 to 29.81) or reduction in seizure frequency (-6.6%;
95% CI -93.7 to 80.5), even after exclusion of a patient with only
complex partial seizures (OR 2.00; 95%CI 0.13 to 31.98; -20.7%
95% CI -101.6 to 60.2).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Centromedian thalamic nucleus stimulation for refractory epilepsy
Patient or population: patients with refractory (multi)focal or generalized epilepsy
Settings: epilepsy centers in the United states and in Mexico
Intervention: centromedian thalamic nucleus stimulation
Comparison: sham stimulation
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Sham stimulation Centromedian thalamic
nucleus stimulation
Seizure freedom
(3-month blinded evalua-
tion period)
Observed in Fisher 1992 OR 1.00 (0.11 to 9.39) 6 (1)1 ⊕©©©
very low1,2
0 per 6 0 per 6
(not estimable)
Low risk population
1 per 1000 1 per 1000
(0 to 9)
High risk population
15 per 1000 15 per 1000
(2 to 125)
Responder rate
(3-month blinded evalua-
tion period)
Low risk population OR 1.00
(0.27-3.69)
6 (1) ⊕©©©
very low1,2,3
10 per 100 10 per 1000
(3 to 29)
Medium-high risk population2
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25 per 100 25 per 1000
(8 to 55)
Seizure frequency re-
duction
(3-month blinded evalua-
tion period)
The mean seizure fre-
quency reduction in the
control group was -0.4%
The mean seizure fre-
quency in the intervention
groups was
+7.1% higher
(-44.1% lower to +58.
2% higher)
6 (1) ⊕©©©
very low1,2,3
Also another trial (
Velasco 2000) (n=13)
could not demonstrate
significant differences be-
tween stimulation ON and
OFF periods. However, its
cross-over design with-
out any washout period
could mask a possible
treatment effect
Adverse events See comment See comment 19 (2)
21 (2)
⊕⊕©©
low2,4
Stimulation-related ad-
verse events did not oc-
cur.
Postoperative CT re-
vealed an asymptomatic
and minimal haemor-
rhage in one patient, 1 pa-
tient required repair of the
connection to the pulse
generator and skin ero-
sion urged device explan-
tation in 3 other patients
(including 2 young chil-
dren)
Neuropsychological out-
come
(3 months)
See comment See comment 6 (1) ⊕©©©
very low1,2
There were no significant
differences in any of the
neuropsychological tests
between baseline, stimu-
lation ON and OFF periods
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Quality of life See comment See comment 0 (0) See comment Impact of centromedian
thalamic nucleus stimula-
tion on quality of life has
not been studied yet
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Cross-over trial(s).
1 No more than one small RCT was identified, resulting into wide 95% confidence intervals (GRADE score -2). This is of particular
concern for neuropsychological outcome, as no exact figures were reported or could be provided, so evaluation of certain statistically
non-significant trends is not possible.
2 Only 2 hours of intermittent stimulation per day in Fisher 1992 (GRADE score -1).
3 Incomplete outcome data may introduce bias (GRADE score -1).
4 Number of subjects too low to identify less frequent adverse events (GRADE score -1)
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Cerebellar stimulation for refractory epilepsy
Patient or population: patients with refractory (multi)focal or generalized epilepsy
Settings: epilepsy centers in the United States and in Mexico
Intervention: scheduled stimulation of the superomedial surface of the cerebellum
Comparison: sham stimulation
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Sham stimulation Cerebellar stimulation
Seizure freedom
(1- to 3-month blinded
evaluation period)
Observed OR 0.96
(0.22 to 4.12)
22 (3)1 ⊕⊕⊕©
moderate2
0 per 19 0 per 20
(not estimable)
Low risk population
1 per 1000 1 per 1000
(0 to 4)
High risk population
15 per 1000 14 per 1000
(3 to 59)
Responder rate
(1- to 3-month blinded
evaluation period)
Low risk population OR 2.43
(0.46 to 12.84)
19 (3)1 ⊕⊕©©
low2,3
10 per 100 21 per 100
(5 to 59)
Medium-high risk population
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25 per 100 45 per 100
(13 to 81)
Seizure frequency re-
duction
(1- to 3-month blinded
evaluation period)
The mean seizure fre-
quency reduction ranged
across control groups
from 0 to -18.8%
The mean seizure fre-
quency in the intervention
groups was
-12.4% lower
(-35.3% lower to +10.
6% higher)
19 (3)1 ⊕⊕©©
low2,3
Adverse events See comment See comment 22 (3)1 ⊕⊕©©
low2,4
Stimulation-related ad-
verse events were not re-
ported in any of the trials
In contrast, about half of
the patients in every trial
required repeated surgery
due to electrode migra-
tion (n=6), leakage of
cerebrospinal fluid (n=
3), wound infection (n=
1), skin erosion (n=2)
, lead problems (n=1)
, subcutaneous seroma
drainage (n=1) and de-
fective hardware (n=1)
. Wound infections were
solved with antibiotics
only in 2 additional pa-
tients. In particular, elec-
trode migration remains
of specific concern, even
in the most recent trial
(Velasco 2005) (occur-
ring in 3/5 patients).
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Neuropsychological out-
come
(1 to 2 months)
See comment See comment 16 (2)1 ⊕©©©
very low2,3,5
’Psychometry’ did not re-
veal any major change
in any patient in any
phase of the Wright 1984
trial. Comparing ON to
OFF stimulation full scale
intelligence and memory
scores in Van Buren 1978
showed very similar re-
sults in two subjects, a
moderate increase in one
patient and a moderate
decrease in another
Quality of life
(2 months)
See comment See comment 12 (1)6 ⊕©©©
very low2,3,7
Eleven out of 12 patients
in Wright 1984 felt bet-
ter for cerebellar stimu-
lation, but only 5 chose
one phase as being differ-
ent from the others, be-
ing either the continuous
(n=2), contingent (n=1)
or no-stimulation (n=2)
phase
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; OR: odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Including 2 cross-over trials: Van Buren 1978 (n=4-5) and Wright 1984 (n=9-12)
2 The small number of patients leave a considerable amount of uncertainty with regards to stimulation effects.
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3 Two trials are cross-over trials without any washout period, which could mask or reduce potential benefits of cerebellar stimulation
(and explain some heterogeneity).
4 Unclear if, how and to what extent stimulation-related side effects were evaluated in Van Buren 1978 and Wright 1984.
5 Unclear what neuropsychological tests were performed in Wright 1984 (’psychometry’). Moreover, as testing scores were not published
and could not be provided, evaluation of certain statistically non-significant trends is not possible. Unclear if neuropsychological testing
in Van Buren 1978 was done in blinded or unblinded evaluation periods.
6 Cross-over trial: Wright 1984 (n=12).
7 No formal scoring of quality of life but evaluation of patients’ impressions on cerebellar stimulation.
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Hippocampal stimulation for refractory epilepsy
Patient or population: patients with refractory medial temporal lobe epilepsy
Settings: epilepsy centers in Canada and in Mexico
Intervention: hippocampal deep brain stimulation
Comparison: sham stimulation
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Sham stimulation Hippocampal stimula-
tion
Seizure freedom
(1- to 3-month blinded
evaluation periods)
Observed OR 1.03
(0.21 to 5.15)
15 (3)1 ⊕⊕⊕©
moderate2
0 per 11 0 per 10
(not estimable)
Low risk population
1 per 1000 1 per 1000
(0 to 5)
High risk population
15 per 1000 15 per 1000
(3 to 73)
Responder rate
(1- to 3-month blinded
evaluation periods)
Low risk population OR 1.20
(0.36 to 4.01)
15 (3)1 ⊕⊕©©
low2,3
10 per 100 12 per 100
(4 to 31)
Medium-high risk population
3
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25 per 100 29 per 100
(11 to 57)
Seizure frequency
(1- to 3-month blinded
evaluation periods)
The mean change in
seizure frequency ranged
across control groups
from -4.7% to +33.7%
The mean seizure fre-
quency in the intervention
groups was
-28.1% lower
(-34.1 to -22.2% lower)
15 (3)1 ⊕⊕⊕©
moderate2
One study has some risks
of bias which could result
into an underestimation of
the true treatment effect.3
Adverse events See comment See comment 15 (3)1 ⊕⊕©©
low4
There were neither stim-
ulation-related adverse
events, nor early surgical
complications. Skin ero-
sion and local infection
required explantation after
>2 years in 3/9 patients
in Velasco 2007.
Neuropsychological out-
come
(1- to 3-month periods)
See comment See comment 6 (2)1 ⊕©©©
very low3,4
Neuropsychological test
results were the same or
very similar during stimu-
lation ON and OFF periods
in Tellez-Zenteno 2006
(n=4) and in one pa-
tient in McLachlan 2010.
The other patient in
McLachlan 2010 showed
worse verbal and visu-
ospatial memory scores
when stimulated, notwith-
standing that he re-
ported subjective mem-
ory improvement during
the same period
3
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Quality of life
(QOLIE-89)
(1- to 3-month periods)
The mean QOLIE-89
score in the control group
was 60
ThemeanQOLIE-89 in the
intervention group was -5
lower (-53 lower to +43
higher).
3 (1)5 ⊕©©©
very low3,4
Positive changes in
QOLIE-89 (quality of
life in epilepsy 89)
scores indicate improve-
ment. Changes of 5-11.
7 have been defined in
literature as being clini-
cally meaningful (Borghs
2012; Cramer 2004;
Wiebe 2002).
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; OR: odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Including two cross-over trials: McLachlan 2010 (n=2) and Tellez-Zenteno 2006 (n=4)
2 The small number of patients preclude more definitive judgements on effects of hippocampal stimulation.
3 One trial (Tellez-Zenteno 2006) had a cross-over design without any washout period and allowed important changes in antiepileptic
drugs, both of which could reduce or mask more important treatment effects. See also ’Sensitivity analyses’.
4 Number of patients is too low to identify less frequent adverse events or changes in neuropsychological outcome or quality of life
(GRADE-score -2).
5 One cross-over trial: Tellez-Zenteno 2006 (n=3)
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Closed-loop stimulation of the ictal onset zone for refractory epilepsy
Patient or population: adults with refractory focal epilepsy (1 or 2 epileptogenic regions)
Settings: epilepsy centers in the United States
Intervention: responsive stimulation of the ictal onset zone(s)
Comparison: sham stimulation
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Sham stimulation Responsive ictal onset
zone stimulation
Seizure freedom
(3-month blinded evalua-
tion period) a
Observed in Morrell 2011 OR 4.95
(0.23 to 104.4)
191
(1)
⊕⊕⊕©
moderate1
0 per 94 2 per 97
(not estimable)
Low risk population
1 per 1000 5 per 1000
(0 to 95)
High risk population
15 per 1000 70 per 1000
(3 to 614)
Responder rate
(3-month blinded evalua-
tion period)
27 per 100 29 per 100
(18 to 43)
OR 1.12
(0.59 to 2.11)
191
(1)
⊕⊕⊕©
moderate1
3
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Seizure frequency re-
duction
(3-month blinded evalua-
tion period)
The mean estimated
seizure frequency reduc-
tion in the control group
was -17.3%
The mean seizure fre-
quency in the intervention
group was
-24.9% lower
(-40.1 to -6.0% lower)
191
(1)
⊕⊕⊕⊕
high
A trend for increasing ef-
ficacy over time was ob-
served during the blinded
evaluation period and
could result into an un-
derestimation of the treat-
ment effect (treatment ef-
fect of month 3: -32%)
Adverse events See comment See comment 191
(1)
⊕⊕⊕©
moderate1
Adverse events during
the blinded evaluation pe-
riod were rare and there
were no significant differ-
ences between the treat-
ment and control group
Asymptomatic intracra-
nial haemorrhages were
found postoperatively in
3.1% of subjects. During
the entire trial, implant or
incision site infection oc-
curred in 5.2% of partic-
ipants, urging hardware
removal in 2.1% of sub-
jects. Cranial implantation
of the neurostimulator
was the probable cause
of most adverse events,
which include: implant
site pain (16% during the
first year of the trial),
headache (11%), proce-
dural headache (9%) and
dysesthesia (6%). There
were 4 SUDEPs over 340
3
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p-y (11.8 per 1000 p-y),
which is higher than usu-
ally reported in refractory
epilepsy patients (2.2-10
per 1000 p-y) (Tellez-
Zenteno 2005; Tomson
2008). However, the rel-
atively limited number of
p-y preclude firm conclu-
sions
Neuropsychological out-
come
(3 months)
See comment See comment 160-177
(1)
⊕⊕⊕⊕
high
Changes in neuropsy-
chological testing results
were very similar in both
groups and 95% confi-
dence intervals did not in-
clude clinically meaning-
ful differences
Quality of life
(QOLIE-89)
(3-months)
The mean improvement
of the QOLIE-31 score
in the control group was
+2.18.
Themean improvement in
QOLIE-31 score in the in-
tervention group was
-0.14 lower
(-2.88 lower to +2.60
higher)
180
(1)
⊕⊕⊕⊕
high
Positive changes in
QOLIE-89 (quality of
life in epilepsy 89)
scores indicate improve-
ment. Changes of 5-11.
7 have been defined in
literature as being clini-
cally meaningful (Borghs
2012; Cramer 2004;
Wiebe 2002).
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; OR: odds ratio; SUDEP: sudden unexpected death in epilepsy patients; p-y: patient-years
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 More trials and patients are needed to allow more precise estimation of stimulation effects.
2 The confidence interval includes clinically non-significant changes, however, the observed trend for increasing efficacy over time
probably underestimates the treatment effect.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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D I S C U S S I O N
More than 30% of all epilepsy patients have pharmacologically
refractory epilepsy (Kwan and Brodie 2000). Resective surgery is
the first treatment of choice for these patients. However, most pa-
tients are not suitable surgical candidates, some are reluctant to
undergo brain surgery, and many do not achieve long-term seizure
freedom (de Tisi 2011; Engel 2003). Other treatment options in-
clude vagus nerve stimulation, following a specific diet (for exam-
ple a ketogenic diet) and inclusion in trials with newly developed
drugs.However, these options yield seizure freedom in only a small
minority of patients. Invasive brain stimulation, including deep
brain and cortical stimulation, may be an alternative treatment for
these patients. Open-label trials have often shown promising but
at the same time mixed results, and in addition are at high risk
of bias. To increase our understanding of the efficacy and safety
of invasive brain stimulation we performed a systematic review of
the literature selecting only randomized controlled trials (RCTs).
Summary of main results
For a more detailed summary, see Summary of findings for the
main comparison; Summary of findings 2; Summary of findings
3; Summary of findings 4; Summary of findings 5.
We identified nine RCTs which met our eligibility criteria and
could be included in the meta-analysis, including one trial on an-
terior thalamic nucleus DBS for (multi)focal epilepsy (n = 109),
one trial on centromedian thalamic DBS for (multi)focal or gen-
eralized epilepsy (n = 7; 14 treatment periods due to cross-over
design), three trials on cerebellar stimulation for (multi)focal or
generalized epilepsy (n = 22; 39 treatment periods), three RCTs
on hippocampal DBS for medial temporal lobe epilepsy (n = 15;
21 treatment periods) and one trial on responsive stimulation of
the ictal onset zone (one or two epileptogenic regions) (n = 191).
In addition, the results of one RCT on centromedian thalamic
DBS for (multi)focal or generalized epilepsy (n = 13; 26 treatment
periods) were qualitatively described as the unavailability of exact
figures prevented inclusion in the meta-analysis. All trials com-
pared stimulation to sham stimulation. For reasons of clinical het-
erogeneity, we did not combine results across different stimulated
targets but pooled data, if applicable, per individual target.
Statistically significant effects on seizure freedom during the BEPs
(one to three months) could not be demonstrated for any target.
However, the small number of trials and patients cannot exclude
the possibility of clinically meaningful improvements for any tar-
get. Nevertheless, it should be noticed that across all different trials
only three patients were seizure-free for the duration of the BEP.
Two of these belonged to the treatment group of the RCT evaluat-
ing closed-loop stimulation of the ictal onset zone (OR 4.95; 95%
CI 0.23 to 104.4) and another to the sham group of the trial on
anterior thalamic nucleus DBS (OR 0.33; 95% CI 0.01 to 8.35).
Besides seizure freedom, the 50% responder rate was our other
primary outcome measure. Statistically significant effects on re-
sponder rates after one to three months of stimulation could not
be observed for any target, but again the wide CIs cannot ex-
clude clinically meaningful changes for either the stimulation or
the control group. The fact that ORs were ≥ 1.00 in every single
trial and > 1.00 for every target (except for centromedian thalamic
DBS: OR 1.00; 95% CI 0.27 to 3.69) do not suggest equivalence.
However, apart from cerebellar stimulation (OR 2.43; 95% CI
0.46 to 12.84), the pooled effect estimates seem of little clinical
importance for anterior thalamic nucleus DBS (OR 1.20; 95%
CI 0.52 to 2.80), hippocampal DBS (OR 1.20; 95% CI 0.36 to
4.01) and responsive ictal onset zone stimulation (OR 1.12; 95%
CI 0.59 to 2.11).
Statistically significant seizure frequency reductions were demon-
strated for anterior thalamic DBS (-17.4%; 95% CI -32.1 to -
1.0), hippocampal DBS (-28.1%; 95% CI -34.1 to -22.2) and
responsive ictal onset zone stimulation (-24.9%; 95% CI -40.1 to
-6.0). When interpreting these results, one should keep in mind
that these effect estimates may be rather conservative due to ob-
served trends for increasing efficacy over time for anterior thalamic
DBS (month 1: -10%, month 3: -29%) and responsive ictal onset
zone stimulation (month 1: -9%, month 3: -32%) and a possible
outlasting effect in the stimulation ’off ’ period in Tellez-Zenteno
2006, a (high-weighted) cross-over trial on hippocampal DBS
without any washout period. Significant reductions could not be
demonstrated for cerebellar (-12.4%; 95% CI -35.3 to 10.6%) or
centromedian thalamic (+7.1%; 95% -44.1 to 58.2%; no effect in
another cross-over trial (Velasco 2000), P = 0.23) stimulation, al-
though the small number of patients and possible carryover effects
in stimulation ’off ’ periods in Velasco 2000 (centromedian thala-
mic DBS), Van Buren 1978 and Wright 1984 (cerebellar stimu-
lation) preclude more definitive judgements.
Only for anterior thalamic DBS there were statistically significant
differences in stimulation-related adverse events. These included
(treatment versus control group) depression (14.8% versus 1.8%;
P = 0.02), subjective memory impairment (13.8% versus 1.8%;
P = 0.03) and epilepsy-related injuries (7.4% versus 25.5%; P =
0.01). In addition, confusional state and anxiety were more fre-
quent, and standard stimulation parameters could be inappropri-
ate and increase seizure frequency in a small minority of patients.
For the other targets, stimulation-related adverse events did not
occur (centromedian thalamic DBS, cerebellar and hippocampal
stimulation) or were very rare and not significantly more prevalent
in the treatment group (responsive ictal onset zone stimulation).
In general, however, the size of the included studies (in particular
those on centromedian thalamicDBS, cerebellar and hippocampal
stimulation) is too limited to make more conclusive statements,
although responsive ictal onset zone stimulation seems to be well
tolerated except perhaps for the SUDEP rate. The SUDEP rate
was 2 per 325 (6.2 per 1000) patient-years with stimulation ’on’
for anterior thalamic DBS and 4 per 340 (11.8 per 1000) pa-
tient-years for responsive ictal onset zone stimulation compared to
2.2 to 10 per 1000 patient-years as usually reported in refractory
40Deep brain and cortical stimulation for epilepsy (Review)
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epilepsy patients (Tellez-Zenteno 2005; Tomson 2008). Although
the limited number of patient-years prevent firm conclusions on
this issue, close monitoring is certainly indicated for the latter.
The invasive nature of direct brain stimulation treatments resulted
in various surgery- or device-related adverse events. In the two
largest trials, asymptomatic intracranial haemorrhages were de-
tected postoperatively in 3.1% to3.7%of participants and implant
or incision site infection occurred in 5.2% to 12.7% resulting in
hardware removal in 2.1% to 8.2% (Fisher 2010; Morrell 2011).
Inadequate stereotactic placement of electrodes needed repeated
surgery in 8.2% of patients in Fisher 2010. Electrode migration
seems of particular concern for cerebellar stimulation electrodes
(n = 6/22). Other adverse events included skin erosions, defective
hardware, leakage of cerebrospinal fluid, a lead causing pain and a
subcutaneous seroma. Cranial implantation of the neurostimula-
tor in Morrell 2011 was associated with implant site pain (16% in
year one), headache (11%), procedural headache (9%) and dyses-
thesia (6%).
Statistically significant differences in formal neuropsychological
testing results could not be demonstrated on the group level for
any target. However, only for responsive ictal onset zone stimula-
tion there is reasonable evidence for the absence of adverse neu-
ropsychological sequelae. In contrast, the higher prevalence of de-
pression and subjective memory impairment with anterior thala-
micDBS (see above) and the lownumber of (neuropsychologically
tested) participants in studies on centromedian thalamic DBS,
cerebellar and hippocampal stimulation urge further research. In
this respect, it should be mentioned that one (n = 1/6) patient
receiving hippocampal stimulation showed objective worsening
of memory scores although he reported a subjective memory im-
provement. In addition, results were often incompletely published
and the content of the neuropsychological test battery was not
clear for Wright 1984 (cerebellar stimulation).
Anterior thalamic nucleus DBS and responsive ictal onset zone
stimulation do not significantly improve or worsen quality of
life after three months of stimulation. With regards to the other
targets, only one trial on hippocampal stimulation (n = 3)
(Tellez-Zenteno 2006) has formally evaluated quality of life, while
inWright 1984 the patients’ impressions on cerebellar stimulation
were described. Although no clear and unambiguous impact on
quality of life was found, data are too sparse to make any sensible
conclusion.
Quality of the evidence
For a more detailed assessment of the quality of the evidence
see Summary of findings for the main comparison; Summary
of findings 2; Summary of findings 3; Summary of findings 4;
Summary of findings 5.
Several factors affect the quality of currently available evidence. Of
major importance is the limited number of trials, which in addi-
tion mostly have very small sample sizes. Although this holds true
for every target, this is of particular concern for centromedian tha-
lamic DBS, cerebellar and hippocampal stimulation. Moreover,
neuropsychological testing and assessment of quality of life were
only performed in a subset of trials. These limitations make it
harder to demonstrate statistical significance of clinically mean-
ingful differences or to exclude the possibility of such improve-
ments when clinically non-meaningful differences are found.
In four cross-over RCTs on cerebellar (n = 2/3), centromedian
thalamic (n = 1/2) and hippocampal (n = 1/3) DBS there was no
washout period before outcome measures were evaluated during
stimulation ’off ’ periods (Tellez-Zenteno 2006; Van Buren 1978;
Velasco 2000; Wright 1984). As some or all patients had previ-
ously been stimulated and findings consistent with a carryover ef-
fect of invasive neurostimulation have been reported in the litera-
ture (Andrade 2006; Lim 2007; McLachlan 2010; Velasco 2007;
Vonck 2013) thismaymask or reduce possible beneficial or adverse
effects of stimulation. In addition, changes in the antiepileptic
drug (AED) regimen in 3/4 patients during the trial may further
have influenced the results of Tellez-Zenteno 2006 (hippocampal
stimulation). A sensitivity analysis excluding those four trials did
not change our main conclusions, although this did result in more
pronounced estimates of stimulation effects for cerebellar (respon-
der rate OR 8.33; 95% CI 0.22 to 320.4; seizure frequency reduc-
tion -36.7%; 95%CI -95.5 to 21.1) and hippocampal stimulation
(responder rate OR 1.75; 95% CI 0.22 to 14.1; if also larger stan-
dard error for McLachlan 2010 for seizure frequency reduction of
-45.7%; 95% CI -85.9 to -5.5). Obviously, in the case of a clear
absence of any effect (for example on seizure freedom) the pos-
sibility of an outlasting effect in these trials does not complicate
interpretation of the results.
The quality of the evidence on centromedian thalamicDBS is very
low. Two RCTs were identified in the literature. However, one trial
(Velasco 2000) (n = 13) evaluated stimulation ’off ’ periods after
six to nine months of stimulation without any washout period.
The trial only studied two outcome measures (seizure frequency
reduction and adverse events), compared blinded stimulation ’off ’
to the three months preceding it (instead of consistently compar-
ing outcomes to blinded stimulation ’on’ periods), and the non-
reporting of exact figures prevented inclusion in themeta-analysis.
In the second trial (Fisher 1992) seven patients received only two
hours of stimulation per day and incomplete outcome data could
have biased the results.
Risk of bias was present or unclear in various other trials. It
was unclear if the neuropsychological outcome in Van Buren
1978 (cerebellar stimulation) was assessed during blinded or un-
blinded evaluation periods; methods for random sequence gen-
eration and allocation concealment were not well described in
Tellez-Zenteno 2006 (hippocampal stimulation) andWright 1984
(cerebellar cortical stimulation), and evidence of selective report-
ing was present in two other trials (Fisher 2010 for anterior tha-
lamic DBS; McLachlan 2010 for hippocampal DBS), although
we think the latter has not greatly affected the results of this re-
41Deep brain and cortical stimulation for epilepsy (Review)
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view. Some trials also reported their results incompletely (mainly
neuropsychological testing results) and without evidence for se-
lective reporting (Fisher 1992 for centromedian thalamic DBS;
Tellez-Zenteno 2006 for hippocampalDBS;Wright 1984 for cere-
bellar cortical stimulation).
As no more than three trials could be identified for each individual
target, we were not able to assess the risk of publication bias.
Overall completeness and applicability of
evidence
Currently available evidence is far from complete. The complete-
ness and applicability of the evidence are highly dependent on its
quality. All factors limiting the quality of the evidence at the same
time limit, to a greater or lesser extent, the completeness and ap-
plicability of the evidence. In this review this is especially the case
for the small number of trials and patients in which deep brain and
cortical stimulation have been studied. Furthermore, only a subset
of trials have evaluated the impact of stimulation on the neuropsy-
chological outcome (seven out of 10 trials, with varying degree
of extensiveness of testing) and on quality of life (only three to
four out of 10 trials). More large and well-designed RCTs are def-
initely needed to demonstrate or exclude benefits and side effects
of invasive brain stimulation therapies. This applies to every single
target although there are important differences between the differ-
ent targeted structures. Taken together, evidence is most complete
for responsive ictal onset zone stimulation, followed by anterior
thalamic DBS, hippocampal DBS, cerebellar cortical stimulation
and finally centromedian thalamic DBS. In addition, several other
targets have yielded promising results in open-label trials but have
not been studied in blinded and randomized conditions (or the
results have not been published yet), for example the subthala-
mic nucleus (Chabardes 2002; Wille 2011), the caudate nucleus
(Chkhenkeli 2004) and the motor cortex (Elisevich 2006).
Trials on cerebellar and centromedian thalamic DBS included
both patients with (multi)focal epilepsy and patients suffering
from generalized epilepsy. In contrast, trials on anterior thalamic
DBS, hippocampal DBS and responsive ictal onset zone stimu-
lation recruited only (multi)focal, temporal lobe and focal (one
or two epileptogenic regions) epilepsy patients, respectively. Al-
though thismakes sense for hippocampalDBS and responsive ictal
onset zone stimulation, further studies are needed to determine if
anterior thalamicDBS could also be useful for generalized epilepsy
patients.
Only Velasco 2000 (centromedian thalamic DBS) recruited a sub-
stantial number of minors; 5/13 or 7/15 patients were between
four and 15 years old. Authors reported that skin erosion may be
of particular concern in children under eight years of age as a re-
sult of the relatively large size of the pulse generator and the leads,
originally designed for an adult population. Of the other trials,
Fisher 1992 (centromedian thalamic DBS), Velasco 2005 (cere-
bellar stimulation) and Velasco 2007 (hippocampal stimulation)
each included one 14 to 16 year old adolescent, whereas in all
other trials all patients were adult. Therefore, current evidence is
basically limited to adult refractory epilepsy patients. Fisher 2010
(anterior thalamic DBS) only allowed adults with normal mental
capacities (intelligence quotient (IQ) > 70). These are important
restrictions which should be taken into consideration when eval-
uating the overall completeness and applicability of current evi-
dence. Furthermore, evidence is limited to stimulation parame-
ters or parameter strategies used in the respective trials and to the
RNS® System (NeuroPace, Mountain View, CA) for responsive
ictal onset zone stimulation.
Besides the low number of trials and patients, the limited duration
of the BEPs (one to three-month stimulation ’on’ periods) rep-
resents a second major gap in the available evidence. This seems
of particular concern for invasive brain stimulation therapies as
increasing efficacy over time has been reported during BEPs in
some RCTs (Fisher 2010; Morrell 2011), during open-label fol-
low-up after completion of RCTs (Fisher 2010; Morrell 2011;
Velasco 2007) and in some small open-label trials (Franzini 2008;
Khan 2009). Various RCTs have followed their patients for many
months or years after the randomized and blinded phase had been
finished and it may be relevant for the reader to cite the results they
reported to illustrate the shortcomings of today’s evidence. Fisher
2010 (anterior thalamic DBS) reported seizure freedom in 0% at
the end of the BEP (n = 54), in 2.0% at the end of the ensuing
nine month open-label period (stimulation parameters adjusted
on an individual basis, AEDs unchanged) (n = 99) and in 4.5%
after two years of follow-up (changes in the AED regimen were
allowed) (n = 81). Responder rates were 30%, 43% and 54% re-
spectively, with mean seizure frequency reductions of -40%, -41%
and -56%. Fisher 1992 (centromedian thalamic DBS) observed
a 50% seizure reduction in 3/7 patients (2/7 during the BEP)
after an additional three to 13 months of open-label follow-up
(24 hours of stimulation per day), the mean reduction in seizure
frequency being -30% (-7% during the BEP). With regards to
the same target, Velasco 2000 reported seizure freedom in 1/13
patients (7.7%), a 85% responder rate and a mean 72% seizure
frequency reduction at maximum follow-up (12 to 94 months).
Velasco 2005 (cerebellar stimulation) showed a 50% improvement
in 2/3 patients during the BEP (mean seizure frequency reduc-
tion of 56%) and in 4/5 patients after 12 to 24 months follow-up
(68% reduction). The most spectacular improvement was found
in Velasco 2007 (hippocampal stimulation) who reported seizure
freedom in 4/9 patients after 18 months follow-up (0/4 during the
BEP), a 50% reduction in all nine patients (1/4 during the BEP)
and amean seizure frequency reduction of -85% (-30% during the
BEP). Finally, three-month seizure freedom and 50% responder
rate after two years of open-label follow-up (n = 102) in Morrell
2011 (responsive ictal onset zone stimulation) were 7.1% and
46% (mean seizure frequency reduction not reported) compared
to 2.1% and 29% respectively during the BEP. Notwithstanding
that these open-label data often show very favourable results, we
42Deep brain and cortical stimulation for epilepsy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
would like to emphasize that at the same time these are at high
risk of bias, including but not limited to placebo effects and im-
provements due to changes in AED or spontaneous evolution of
the disease (see also below). Only RCTs with more extensive BEP
can unequivocally determine whether and to what extent the effi-
cacy of invasive brain stimulation treatments increases over time.
Meanwhile, we reported for each individual study if and to what
extent such an increasing efficacy over time was observed during
the BEP.
Finally, no trials comparing invasive intracranial neurostimulation
treatments to resective surgery or further treatment with AED
(’best medical practice’) have been published yet.
Potential biases in the review process
We chose to describe the risk of bias present in different trials
rather than excluding all trials with some ’acceptable’ risk of bias.
Given the limited number of RCTs on deep brain and cortical
stimulation published in the literature, we thought such an ap-
proach would be more useful to the reader than just concluding
that more well-designed trials are needed. However, such an ap-
proach adds some risk of bias to the review process. This remark
holds particularly true for the inclusion of four cross-over trials
without any washout period and therefore at (unknown) risk of
bias due to an outlasting effect after stimulation. We therefore per-
formed a sensitivity analysis excluding these trials. Although this
resulted in a slightly more favourable effect estimate, it did not
change the review’s main conclusions.
As empty cells hinder calculation of odds ratios (seizure freedom,
responder rate), it is customary to add +0.5 to each cell if appli-
cable (Deeks 2011). However, given the small number of patients
included in most trials, this approach may have biased our results.
A sensitivity analysis adding +0.25 instead of +0.5 did not change
our main conclusions but did increase the degree of uncertainty
around the effect estimates for seizure freedom.
For cerebellar and hippocampal stimulation, results of BEPs with
different durations (one to three months) were pooled. As some
reports have suggested increasing efficacy over time this may have
lead to an overestimation compared to the one-month treatment
effect and an underestimation compared to the three-month treat-
ment effect.We therefore refer to the observed treatment effects as
occurring after ’one to three months’ of stimulation. In addition,
we described in the text if and to what extent increasing efficacy
over time was observed during the BEP of each individual trial.
For future RCTs with longer BEPs we plan to pool results per
three-month epoch (for example month one to three, month four
to six).
Agreements and disagreements with other
studies or reviews
Although various non-systematic reviews have been published the
past years, to our knowledge this is the first systematic review on
RCTs studying deep brain and cortical stimulation. The non-sys-
tematic reviews also discussed uncontrolled, often unblinded tri-
als. In this regard, it is appealing that these trials have often yielded
much more favourable results than RCTs. Besides the placebo ef-
fect, several other factors may account for this discrepancy. First of
all, RCTs compare real stimulation to sham stimulation whereas
in uncontrolled trials baseline seizure frequency is taken for the
reference data. Accordingly, seizure frequency reductions due to
(temporary) implantation effects (Fisher 2010; Hodaie 2002;Lim
2007; Morrell 2011) and microlesions resulting from electrode
insertion (Boëx 2011; Katariwala 2001; Schulze-Bonhage 2010)
contribute to the observed treatment effects in uncontrolled trials
whereas they do not in RCTs. Second, uncontrolled trials have
longer follow-up periods and increasing efficacy over time has been
suggested (see above). However, one should realize that medica-
tion-induced and spontaneous improvements can be quite impres-
sive on a group level (Neligan 2012; Selwa 2003) and therefore
are likely to contribute to the more favourable results obtained in
uncontrolled trials. Third, the cross-over design used in four RCTs
may undervalue the efficacy of neurostimulation treatments, as
discussed above. Finally, further improvements due to optimiza-
tion of stimulation parameter settings have been reported (Boëx
2011; Vonck 2013; Wille 2011) and uncontrolled trials often use
variable parameter settings whereas RCTs have a fixed stimulation
protocol. In conclusion, it is likely that several factors overesti-
mate the efficacy of invasive neurostimulation in uncontrolled tri-
als whereas some others may contribute to an underestimation of
its full potential in RCTs.
Vagus nerve stimulation is another type of invasive neurostimu-
lation which nowadays has become routinely available in many
epilepsy centres worldwide. Although the treatment effects re-
ported in two large RCTs (-12.7% and -18.4%) (Handforth 1998;
VNS Study Group 1995) were similar or slightly inferior to those
of anterior thalamic DBS (-17.4%), hippocampal DBS (-28.1%)
and closed-loop ictal onset zone stimulation (-24.9%), a Cochrane
Review on vagus nerve stimulation (including only those two tri-
als) did demonstrate a significant higher responder rate with va-
gus nerve stimulation using a high stimulation paradigm (’stan-
dard stimulation’) compared to a low stimulation paradigm (’sham
stimulation’) (OR 1.93; 95% CI 1.1 to 3.4) (Privitera 2002). As
outlined above, we did not find such a significant improvement
for any intracranial target.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Making general recommendations about the practical usefulness
of intracranial neurostimulation treatments implies making trade-
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offs between potential benefits and harms, costs, healthcare re-
sources and alternative treatments such as newly developed drugs,
the ketogenic diet, vagus nerve stimulation and epilepsy surgery.
We believe such a trade-off should be made on an individual pa-
tient basis, differing from country to country, and therefore goes
beyond the scope of this review. In this section we will conse-
quently only focus on available evidence on the benefits and harms
of intracranial neurostimulation treatments.
Of all potential intracranial targets, only five have been studied in
randomized and double-blind conditions so far. The main limi-
tation is the number of trials, which in addition mostly have very
small sample sizes and are of short duration. Nevertheless, high-
quality evidence is available that three months of anterior tha-
lamic nucleus DBS and responsive ictal onset zone stimulation
can reduce seizure frequency in refractory (multi)focal epilepsy
patients, whereas moderate-quality evidence shows the same for
one to three months of hippocampal DBS in refractory temporal
lobe epilepsy patients. However, compared to sham stimulation,
the observed improvements were moderate (ranging between 17%
and 28%) and there is no evidence for either a clinically or statisti-
cally significant impact on seizure freedom, responder rate or qual-
ity of life (although anterior thalamic DBS did reduce epilepsy-
associated injuries). Given these rather moderate improvements,
possible harms should be carefully considered. Anterior thalamic
DBS and responsive ictal onset zone stimulation were in gen-
eral safe and well-tolerated, but 1) anterior thalamic DBS was as-
sociated with statistically significant higher incidences of self-re-
ported depression (no group-level changes in objective measures)
and subjective memory impairment (no group-level changes in
objective measures) besides statistically non-significant increases
in anxiety, confusional state and seizure frequency in some pa-
tients; and 2) SUDEP rate should be closely monitored in future
for responsive ictal onset zone stimulation. Hippocampal DBS
seemed safe and relatively well-tolerated in 15 patients but these
findings should be confirmed in more larger trials, with particular
concern for memory impairment (found in 1/6 neuropsycholog-
ically tested patients). Besides stimulation-related side effects, the
invasive nature of these treatments resulted in soft tissue infections
and asymptomatic intracranial haemorrhages, but no permanent
symptomatic sequelae resulting from electrode implantation were
reported. Finally, when balancing benefits and risks of the afore-
mentioned treatments one should keep in mind that many of the
patients included in the trials on intracranial neurostimulation had
previously turned out to be refractory to various other treatments
(including AED, resective surgery and vagal nerve stimulation)
and most of them probably had no other treatment options.
Besides the three targets mentioned in the previous paragraph,
centromedian thalamic nucleus DBS and cerebellar cortical stim-
ulation have been studied in RCTs but no significant effects were
found in these small trials, which in addition suffered from various
other limitations. In conclusion, there is insufficient evidence to
accept or refuse their efficacy or tolerability. No trials comparing
intracranial stimulation to ’best medical practice’ or surgery have
been published yet.
Finally, it is remarkable that non-randomized unblinded trials on
intracranial neurostimulation treatments have often reportedmore
favourable results. However, these trials probably overestimate the
treatment effect attributable to stimulation. At the same time,
some factors may have underestimated the true treatment effect
in RCTs, such as the cross-over design, individually suboptimal
stimulation parameter settings and the short duration of follow-
up. These last statements, however, have not been studied in ran-
domized and double-blind conditions and therefore remain spec-
ulative.
Implications for research
Given the limited number of RCTs identified in the literature,
more randomized double-blind controlled clinical trials are re-
quired to provide evidence on the efficacy and safety of intracranial
neurostimulation treatments for refractory epilepsy. These trials
should preferably:
• include large numbers of patients. However, given the
limited number of patients included in RCTs so far, even smaller
trials would increase the available evidence and are therefore
worthwhile to be undertaken. For the same reason, results of
preliminary terminated trials (e.g. due to insufficient patient
enrolment) should be published;
• make interpretation easier by avoiding possible outlasting
effects of stimulation. The most straightforward way to do so is
using a parallel study design. When a cross-over design is used,
due to difficulties in patient recruitment, a washout period
should be introduced (e.g. three months without stimulation
after three months of stimulation);
• make interpretation easier by avoiding possible
implantation effects (as in Fisher 2010 and Morrell 2011) by
using a sufficient time window (e.g. four months) between
electrode implantation and the start of the blinded evaluation
period;
• assess and report all significant outcome variables, including
seizure freedom, responder rate, seizure frequency reduction,
adverse events, neuropsychological outcome and quality of life.
Additionally, there is a need for RCTs comparing intracranial neu-
rostimulation treatments to ’best medical practice’ (including va-
gal nerve stimulation); reported trends for increasing efficacy over
time should be verified in randomized and if possible double-blind
conditions (comparison to ’best medical treatment’ could over-
come ethical issues); and, finally, more efforts should be made to
identify optimal stimulation parameter paradigms, which could
be patient-specific.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Fisher 1992
Methods Double-blind balanced cross-over randomized controlled trial
• prospective baseline seizure frequency recording for several months
• electrode implantation
• stimulators OFF until randomization 1 to 2 months postoperatively
• cross-over design of 3-month treatment blocks (receiving each treatment once)
with a 3-month washout phase
• long-term open-label follow-up with stimulation ON in all patients
Participants n=7, 42.9%male, mean age 28.0 years (range 16-41y), duration of epilepsy ranged from
14 to 29 years
2 patients with focal epilepsy (one with and one without secondary generalization), 5
patients with generalized epilepsy (2/5 had Lennox-Gestaut syndrome); poor candidates
for resective surgery
mean baseline seizure frequency of 23.4 (SD 15.9) seizures per month
Interventions Active: bilateral stimulation of the centromedian thalamic nucleus
• output voltage was set to half the sensory threshold and ranged from 0.5 to 10 V
• stimulation frequency of 65 Hz
• pulse width 90 µsec
• 1 minute of bipolar stimulation each 5 minutes for 2 hours per day
Control: sham stimulation (output voltage set at zero)
Outcomes (1) Proportion of participants who were seizure-free
(2) Proportion of participants with a ≥ 50% seizure frequency reduction (responder
rate)
(3) Seizure frequency reduction
(4) Adverse events (spontaneous reporting, postoperative CT scan)
(5) Neuropsychological outcome [tests of general intelligence (WAIS-R), speech and
language functions (the Boston Naming Test, the Controlled Oral Word Association
Test, a written description of theCookie Theft Picture from the BDAE), visual and verbal
memory functions (the Weschler Memory Scale, the Rey Auditory Verbal Learning Test
with delayed recall and the Warrington Recongnition Memory Test (words and faces)
), parietal lobe-type functions (the Rey Osterreith Complex Figure Test with delayed
recall), frontal lobe-type functions (the Wisconsin Card Sorting Test) and psychomotor
functions (the Trial Making Test (A and B) and the Perdue Grooved Pegboard)]
Notes the study was supported by Medtronic Inc. (Minneapolis, MN) who also donated hard-
ware for the protocol
Risk of bias
Bias Authors’ judgement Support for judgement
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Fisher 1992 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “patients were randomized to either
stimulation ON for A and OFF for B or to
stimulation OFF for A and ON for B”
Personal communication: “envelopes were
chosen at random picking from a pile for
each patient”
Allocation concealment (selection bias) Low risk Quote: “randomization order was provided
in a sealed envelope”
Personal communication: sealed and se-
quentially numbered envelopes, unclear if
they were specific opaque envelopes (study
was conducted more than 20 years ago);
however, randomization was performed by
a third person, not involved in selecting,
treating or evaluating patients
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “neither patient, families, treat-
ing medical team nor data analysts knew
whether the stimulator was ON or OFF
during phases A and B”; “patients could
not detect when stimulation was ON or
OFF”; “stimulation was set to half the sen-
sory threshold”; “a single unblinded in-
dividual was aware of treatment parame-
ters and tested stimulator function at each
monthly visit”
Personal communication: the single un-
blinded individual was not involved in
treating or evaluating patients
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: see above; seizure frequencywas
recorded in a seizure calendar
Incomplete outcome data (attrition bias)
All outcomes
High risk One of the two patients who improved
markedly with centromedian thalamic
stimulation experienced several episodes of
multiple daily seizures in the washout pe-
riod and therefore was dropped from the
blinded protocol and stimulation was rein-
stalled. As there were only seven patients,
with only two responders, this one patient
represents a significant proportion
Selective reporting (reporting bias) High risk - The results of a statistical analysis includ-
ing all patients, to evaluate the efficacy of
the intervention on seizure frequency, are
not reported. Instead, only the results of
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Fisher 1992 (Continued)
an analysis including all patients with (pri-
marily or secondarily) generalized seizures
are presented (thus excluding one patient
with only complex partial seizures). This
was not prespecified in the Methods sec-
tion. However, as all raw data are present
in the article, all information necessary for
this review is available
- Concerning the neuropsychological out-
come: “multivariate analysis with repeated
measures showed no significant differences
in any measure between baseline, placebo
(OFF) and treatment (ON) conditions”
Personal communication: exact figures no
longer available
Comment: no exact figures were reported,
probably because there was too much data
for a journal article (rather incomplete than
selective reporting)
Outlasting effect due to prior stimulation Low risk Comment: cross-over design, but with a 3-
month washout period
Anti-epileptic drug policy Low risk Quote: “AED dosages were kept constant
throughout the study”
Fisher 2010
Methods Multicentre, double-blind, parallel-design, randomized controlled trial:
• 3-month baseline period
• electrode implantation
• 1 month of recovery
• 3-month blinded randomized phase during which half of subjects received
stimulation and half did not; stimulation parameters and AEDs were kept constant
• 9 months open-label unblinded stimulation in all patients; AEDs were kept
constant but limited stimulation parameter changes were allowed
• long-term follow-up unblinded stimulation in which AEDs and stimulation
parameters could vary freely
Participants n=109, 50.0% male, mean age 36.1 years (inclusion criterion:18-65 y), mean duration
of epilepsy was 22.3 (SD 13.3) years;
all patients suffered from partial-onset epilepsy (partial seizures and/or secondarily gen-
eralized seizures), IQ > 70 in all patients, 24.5% and 44.5% had prior resection and
vagus nerve stimulation, respectively;
median baseline seizure frequency of 19.5 seizures per month (inclusion criterion: ≥6
seizures)
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Fisher 2010 (Continued)
Interventions Active: bilateral anterior thalamic nucleus stimulation
• stimulation intensity was set at 5 V
• stimulation frequency of 145 Hz
• pulse width of 90 µsec
• intermittent (1 min ON, 5 min OFF) monopolar cathodal stimulation
Control: sham stimulation
Outcomes (1) Proportion of participants who were seizure-free
(2) Proportion of participants with a ≥ 50% seizure frequency reduction (responder
rate)
(3) Seizure frequency reduction
(4) Adverse events (based on spontaneous reporting by patients, postoperative MRI)
(5) Neuropsychological outcome (attention, executive function, verbal memory, visual
memory, intelligence, expressive language, depression, tension / anxiety, total mood
disturbance, confusion, subjective cognitive function)
(6) Quality of life (QOLIE-31)
Notes the study was supported by Medtronic Inc. (Minneapolis, MN)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomization was done by a cen-
tral statistical site, using random numbers
tables, a one-to-one allocation to active
stimulation versus control, balanced at each
study site and with no weighting for any
subject characteristics”
Allocation concealment (selection bias) Low risk Quote: “randomization was done by a cen-
tral statistical site”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “no care or assessment personnel
knew the voltage settings” and “participants
were unaware of their treatment group”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “no care or assessment personnel
knew the voltage settings”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 108 out of 109 randomized patients com-
pleted the blindedphase.One patient (con-
trol group) developed an infection requir-
ing explant, but was included in all analyses
as randomized
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Fisher 2010 (Continued)
Selective reporting (reporting bias) High risk Quote: “Changes in additional outcome
measures did not show significant (...) dif-
ferences during the double-blind phase,
including 50% responder rates, Liverpool
Seizure Severity Scale and Qulatiy of Life
in Epilepsy scores”
Comment 1: not all available (as can be de-
ducted from the online “Medtronic DBS
therapy for epilepsy sponsor information”,
www.fda.gov) outcome measures (includ-
ing seizure-free days and seizure-free inter-
vals) were mentioned or reported in the pa-
per in Epilepsia
Comment 2: different analyses were per-
formed, most of which were prespecified,
although one was not. This unprespeci-
fied analysis excluded one patient of the
treatment groupwho experienced amarked
seizure frequency increase. However, as
there were good reasons to do so and the re-
sults of the other prespecified analysis were
also reported, we do not consider this as a
major source of selective reporting
Outlasting effect due to prior stimulation Low risk Comment: parallel-group design, no stim-
ulation prior to the randomized phase
Anti-epileptic drug policy Low risk Quote: “medication were kept constant
during the 3-month blinded phase and the
9-month unblinded phase”
McLachlan 2010
Methods Double-blind balanced cross-over randomized controlled trial
Total duration 15 months:
• implantation of the electrodes
• 3-month baseline period without stimulation
• 3 months ON / OFF (randomized)
• 3-month washout period (if ON)
• 3 months OFF / ON (opposite of month 4-6)
• 3-month washout period (if ON)
Participants n=2, 50% male, 45 and 54 years old, duration of epilepsy was 15 and 29 years;
medically intractable focal epilepsy, poor candidates for resective surgery on the basis
of independent bitemporal originating seizures, normal MRI in patient 1 and bilateral
hippocampal sclerosis in patient 2;
baseline seizure frequency of 32 and 16 seizures per month
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McLachlan 2010 (Continued)
Interventions Active: bilateral hippocampal stimulation
• output voltage was determined by starting at 0.5V and increasing until symptoms
occurred, the voltage was then decreased until it was subthreshold for conscious
appreciation
• stimulation frequency of 185 Hz
• pulse width 90 µsec
• continuous monopolar bilateral stimulation
Control: sham stimulation
Outcomes (1) Proportion of participants who were seizure-free
(2) Proportion of participants with a ≥ 50% seizure frequency reduction (responder
rate)
(3) Seizure frequency reduction
(4) Adverse events (standard questionnaire)
(5) Neuropsychological outcome (objective memory: Hopkins Verbal Learning Test-
Revised and the Brief visuospatial Memory Test-Revised; subjective memory: Memory
Assessment Clinic Self-Rating Scale)
Notes no external funding
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomization of the first treat-
ment”
Personal communication: computer gener-
ated randomized sequences
Allocation concealment (selection bias) Low risk Quote: “randomization of the first treat-
ment was determined independently by the
research unit and placed in a sealed enve-
lope”
Personal communication: sealed, double-
opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “both the treating neurologist and
patient were blind to the stimulator sta-
tus”; “the voltage was decreased until it was
subthreshold for conscious appreciation so
that patients were unaware of the status of
the stimulator”; “neither patient was able to
accurately assess when the stimulator was
ON or OFF”; “the envelope with the stim-
ulation sequence was given to a neurosur-
geon not involved in outcome assessment
who turned the device ON or OFF at each
3-month visit”
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McLachlan 2010 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: see above, only one neurosur-
geon, not involved in outcome assessment,
knew the stimulator status
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: for the ON- and OFF-period
all data were available; only the objective
memory data of one patient in the washout
period were not available
Selective reporting (reporting bias) High risk Quote: in theMethods section: “differences
in mean monthly seizure frequency were
assessed using repeated measures ANOVA”
; in the Results section: “ANOVA re-
vealed a significant difference in the me-
dian monthly seizure frequency between
the four epochs (p<0.01)”
Comment: unclear why (only) the median
monthly seizure frequency was used in this
analysis instead of all available data, i.e. to-
tal number of seizures (or mean monthly
seizure frequency, as announced in the
Methods section and as was indeed re-
ported as a descriptive variable to quantify
the treatment effect); however, as all avail-
able individual patient data were provided
to us by the author, this had no influence
on this review
Outlasting effect due to prior stimulation Low risk Comment: cross-over study, but with a 3-
month washout phase
Anti-epileptic drug policy Low risk Quote: “(...) antiseizure drugs, which re-
mained unchanged during the study”
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Morrell 2011
Methods Multicenter, double-blind, parallel-design, randomized controlled trial:
• 12-week baseline period
• implantation of the electrodes: 1 or 2 recording and stimulating depth or subdural
cortical strip leads were surgically placed in the brain according to the seizure focus
• 4-week postoperative stabilization period: the neurostimulator was programmed
to sense and record the electrocorticogram, but not to deliver stimulation
• randomization
• 4-week stimulation optimization period: neurostimulators only of patients in the
treatment group were programmed to deliver stimulation (not in the sham group)
• 12-week blinded evaluation period (BEP): treatment versus sham group
• open-label evaluation period: all patients were able to receive responsive
stimulation
Participants n=191, 52% male, mean age 34.9 years (range 18-66 y), duration of epilepsy ranged
from 2 to 57 years
all patients suffered from medically intractable partial onset seizures, 45% had only one
seizure focus and 55% had two seizure foci, 32 and 34% had prior therapeutic surgery
and vagus nerve stimulation, respectively
mean baseline seizure frequency of 1.2 (SD 2.2) seizures per day (inclusion criterion ≥3
seizures per month)
Interventions Active: stimulation directly to the seizure focus in response to epileptiform electrographic
events (device: RNS® System, NeuroPace, Mountain View, CA)
• stimulation parameters were determined individually during the 4-week
stimulation optimization period
• amplitude (range used): 0.5 - 12 mA
• frequency (range used): 2-333 Hz
• pulse width (range used): 40-520 µsec
• responsive stimulation, burst duration (range used): 10-1000 msec
Control: sham stimulation
Outcomes (1) Proportion of participants who were seizure-free
(2) Proportion of participants with a ≥ 50% seizure frequency reduction (responder
rate)
(3) Seizure frequency reduction
(4) Adverse events (as assessed by clinicians, additionally vital signs were collected and a
neurological examination was conducted at every office appointment)
(5) Neuropsychological outcome [visual motor speed (trailmaking part A and B), motor
speed / dexterity (grooved pegboard, dominant and nondominant), auditory attention
(Wechsler Adult Intelligence Scale (WAIS)-III digit span), general verbal ability (WAIS-
III information), general visuospatial ability (WAIS-III block design), verbal memory
(Rey Auditory Verbal Learning Test (RAVLT) I-V, VII (delayed recall) and memory
recognition), visuospatial memory (Brief Visuospatial Memory Test-Revised (BVMT-
R) total recall, delayed recall and recognition discrimination index), language (Boston
Naming Test (60 items) spontaneous with semantic clue; Delis-Kaplan Executive Func-
tion System (D-KEFS) verbal fluency test, condition 1: letter fluency), design fluency
(D-KEFS design fluency, total composite); mood inventories included the Beck Depres-
sion Inventory II (BDI-II) and the Center for Epidemiologic Studies Depression Scale
(CES-D)]
(6) Quality of life (QOLIE-89)
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Morrell 2011 (Continued)
Notes the study was sponsored by NeuroPace Inc., Mountain View, California (USA)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “subjects were assigned 1:1 to treat-
ment or shamgroups using an adaptive ran-
domization algorithm controlling for in-
vestigational site, location and number of
seizure onsets and prior epilepsy surgery”
Personal communication: “computer based
random sequence generation”, “an adaptive
randomization process was used to mini-
mize the imbalance within the covariates
listed above: imbalance was calculated for
each covariate and each potential therapy
allocation, the less-imbalancing therapy al-
location was selected with a 75% probabil-
ity, and the more-imbalancing therapy al-
location was selected with a 25% probabil-
ity”
Allocation concealment (selection bias) Low risk Personal communication: central alloca-
tion, “An adaptive randomization was per-
formed tominimize imbalance (...). So that
therapy allocation could not be guessed or
determined for a given subject (even with
knowledge of the therapy allocation of all
other subjects), the final therapy allocation
for a subject was selected with a 75% prob-
ability towards the less imbalancing alloca-
tion and 25% probability towards themore
imbalancing allocation”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “a blinded physician gathered all
outcome data and a nonblinded physician
managed the neurostimulator”; “to main-
tain the subject blind, all subjects under-
went actual or sham programming of the
neurostimulator to ensure that time with
the physician was similar”; “the blind was
successfully maintained. At the end of the
BEP 24% said that they did not know to
which group they had been randomized,
33% guessed incorrectly and 43% guessed
correctly”
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Morrell 2011 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: see above
Incomplete outcome data (attrition bias)
All outcomes
Low risk Active stimulation group: 95/97 subjects
completed the trial: one patient did not
complete the stimulation optimization pe-
riod (subject preference), one did not com-
plete the BEP (emergent explant)
Sham stimulation group: 92/94 subjects
completed the trial: one patient did not
complete the stimulation optimization pe-
riod (death), one did not complete the BEP
(emergent explant)
Selective reporting (reporting bias) Unclear risk Comment:
- no evidence of selective reporting; study
was registered on www.clinicaltrials.gov
but outcome measures were not men-
tioned;
- concerning the neuropsychological out-
come, quality of life and adverse events, no
or not all exact figures per group (sham ver-
sus treatment group) were reported, they
only mentioned that there were no signif-
icant differences. Probably this was due to
the fact that there was too much data for
publication (rather incomplete than selec-
tive reporting). Authors provided us these
data upon our request
Outlasting effect due to prior stimulation Low risk Comment: parallel-group design, no stim-
ulation prior to the randomized phase
Anti-epileptic drug policy Low risk Quote: “anti-epileptic drugs were to be
held constant through the BEP, and then
could be adjusted as needed; benzodi-
azepines for seizure clusters or prolonged
seizures were permitted”
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Tellez-Zenteno 2006
Methods Double blind, multiple cross-over, constrained (paired) randomized controlled design
• 3-month baseline period (unclear if this was before or after electrode
implantation)
• three 2-month treatment pairs during which the stimulator was randomly
allocated to be ON for 1 month and OFF for 1 month
Participants n=4, 25% male, mean age 31.8 years (range 24-37y), duration of epilepsy ranged from
16 to 24 years
the patients suffered from refractory left unilateral medial temporal lobe epilepsy whose
risk to memory contraindicated temporal lobe resection, all patients showed mesial
temporal sclerosis on MRI
mean baseline seizure frequency of 4, 2.3, 25 and 4 seizures per month
Interventions Active: left hippocampal stimulation
• intensity was determined individually so that it was subthreshold for conscious
appreciation (range 1.8 to 4.5V)
• stimulation frequency of 190 Hz
• pulse width 90 µsec
• continuous monopolar stimulation
Control: sham stimulation
Outcomes (1) Proportion of participants who were seizure-free
(2) Proportion of participants with a ≥ 50% seizure frequency reduction (responder
rate)
(3) Seizure frequency reduction
(4) Adverse events (open questions)
(5) Neuropsychological outcome (this included alternate forms of the Boston Naming
Test; alternate forms of the Digit Span Test; Hopkins Verbal Learning Test; the Brief
Visual Memory Test; Memory Assessment Clinic Self-Rating Scale; due to concerns
with potential floor effects associated with standard neuropsychological memory tests,
one patient underwent some alternative tests; the Center for Epidemiologic Studies
Depression (CES-D) scale was used to assess mood)
(6) Quality of Life (QOLIE-89)
Notes The authors reported no conflicts of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomly allocated”
Allocation concealment (selection bias) Low risk Quote: “randomization to one of the eight
possible sequences was done independently
by the research unit, eachmonth’s sequence
was placed in sealed, double-opaque, se-
quentially numbered envelopes”
59Deep brain and cortical stimulation for epilepsy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Tellez-Zenteno 2006 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “patients, treating clinicians and
outcome assessors were blinded”; “stimula-
tion was set subthreshold for conscious ap-
preciation”; “the patients’ ability to guess
ON or OFF status was no better than
chance”; “a neurosurgeon not involved in
outcome assessment or medical therapy
received one envelope each month and
turned the stimulator ON or OFF”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: see above
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: one patient did not complete
quality of life related assessments; however,
this was the case both during active and
sham stimulation, so no real risk of attrition
bias; all other outcome data were complete
Selective reporting (reporting bias) Unclear risk - Quote: “neuropsychological testing re-
vealed no differences betweenON,OFF or
baseline periods in any of the patients on
any of the formal measures, or in the sub-
jective memory scale”
Comment: exact figures were not reported
for the subjective memory scores (the
Memory Assessment Clinic Self-Rating
Scale) and for none of the test results mea-
sures of variance were provided. However,
this seemsmore a case of incomplete rather
than selective reporting.
- No evidence of selective reporting for
other outcomes, but no protocol available
Outlasting effect due to prior stimulation Unclear risk Comment: multiple cross-over design
without washout period
Anti-epileptic drug policy High risk Comment: anti-epileptic drugs remained
unchanged in only one patient
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Van Buren 1978
Methods Double-blind, multiple cross-over, randomized controlled trial
• preoperative seizure rates were observed in the hospital before implantation
(baseline seizure frequency)
• implantation
• stimulation ON as soon as preoperative seizure frequency had resumed after
surgery
• seizure frequency was evaluated in hospital during 3 or 4 admissions over the
ensuing 15-21 months, each lasting 4 to 6 weeks; this time was made up of 1 or more
weeks of ON-and-OFF stimulation without double-blind conditions and a roughly
similar period of ON-and-OFF stimulation in the double-blind mode; for this review,
only double-blind data were considered (in total 26 days ON and 26 days OFF)
Participants n=5, mean age 27.2 years (range 18-34 y), duration of epilepsy ranged from 8 to 23 years
the patients suffered from medically intractable seizures; seizures were not classified
but described; presumably, four suffered from focal epilepsy with partial seizures (and
secondarily generalized seizures in two patients) and one from generalized epilepsy (with
myoclonic seizures and unresponsive episodes with prolonged bilateral jerking)
mean baseline seizure frequency of 0.6 to 21.2 seizures per day (mean 5.1)
Interventions Active: bilateral stimulation of the superior surface of the cerebellum parallel to and
about 1 cm from either side of the midline
• stimulation was carried out at levels just below that producing sensation referable
to meningeal irritation, usually at 10 to 14 V
• stimulation frequency of 10 Hz (200 Hz in case of myoclonic seizures)
• pulse width not reported
• 8-minute periods of stimulation alternating from one side of the cerebellum to
the other
Control: same procedure, but with inserting an adhesive pad that had a layer of alu-
minium foil within it, which blocked radiofrequency transmission and in this way pre-
vented true stimulation (versus active group: adhesive pad which consisted solely of ad-
hesive plaster)
Outcomes (1) Proportion of participants who were seizure-free
(2) Proportion of participants with a ≥ 50% seizure frequency reduction (responder
rate)
(3) Seizure frequency reduction
(4) Adverse events
(5)Neuropsychological outcome (full scale intelligence quotients andmemory quotients)
Notes no statement concerning external support
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “the pairs of pads (with or without
an aluminium foil within it) were selected
at random”
Comment: probably completely random
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Van Buren 1978 (Continued)
selection (picking one out of two)
Allocation concealment (selection bias) Low risk Quote: “the pairs of pads were marked
with identifying letters”; “the pair contain-
ing the foil was identified in a sealed note,
which was opened only after the patient’s
observation period”
Comment: although it was not mentioned
explicitly, one could expect that the pads
(note: the pads were selected randomly, not
the notes) had an identical appearance (foil
was within it) and the identifying letters
were non-disclosing (as efforts were made
to conceal their meaning)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “double-blind”; “the pairs of pads
were marked with identifying letters”; “the
pair containing the foil was identified in a
sealed note, which was opened only after
the patient’s observation period”
Comment 1: although it was not men-
tioned explicitly, one could expect that the
pads had an identical appearance (foil was
within it) and the identifying letters were
non-disclosing (as efforts were made to
conceal theirmeaning); unclear if the sealed
notes were double-opaque and by whom
they were handled
Comment 2: not mentioned if neuropsy-
chological testing was performed during
the double-blind or the unblinded evalua-
tion period
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: see above
Incomplete outcome data (attrition bias)
All outcomes
Low risk - Although in two patients only three inpa-
tient evaluations were performed (instead
of the four planned), enough data are avail-
able to evaluate the effects of the interven-
tion
- Neuropsychological testing was not per-
formed in one patient (not testable due
to myoclonus), but low risk of attrition
bias as this was the case both during ef-
fective and sham stimulation; incomplete
preoperative neuropsychological testing in
two additional patients, however postop-
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Van Buren 1978 (Continued)
erative evaluations (most important ones)
were complete
Selective reporting (reporting bias) Unclear risk Comment: no evidence of selective report-
ing, but no protocol available
Outlasting effect due to prior stimulation Unclear risk Comment: multiple cross-over study with-
out washout period; inpatient evaluations
after 1 to 21 months of stimulation
Anti-epileptic drug policy Low risk Quote: “serum levels of phenytoin, primi-
done and phenobarbital were verified sev-
eral times during each admission”; “addi-
tional (to the above mentioned drugs) di-
azepamwas given in two patients and etho-
suximide in one patient, but the serum lev-
els were not monitored”
Comment: probably a policy to keep anti-
epileptic drugs / their serum levels un-
changed
Velasco 2000
Methods Double-blind, cross-over randomized controlled trial
• a 3-month baseline period
• electrode implantation
• 6-9 months of stimulation in all patients
• a 6-month randomized double-blind cross-over (2 x 3 months) phase (ON/OFF
or OFF/ON)
• stimulation again ON in all patients
Participants n=13, 62% male, mean age 19.2 years (range 4-31 y), duration of epilepsy ranged from
4 to 33 years
there were 8 patients with Lennox-Gastaut syndrome (suffering mainly from atypical
absences and generalized tonic-clonic seizures), and 5 with refractory localization-related
epilepsy (suffering mainly from complex partial and secondarily generalized seizures)
mean baseline seizure frequency of 1051 (SD 1434) seizures per month (median 119,
interquartile range 56, 2576)
Interventions Active: stimulation of the centromedian thalamic nucleus
• stimulation amplitude of 4-6 V (400-600 µA)
• stimulation frequency of 60 Hz
• pulse width 450 µsec
• one minute of bipolar stimulation, alternating between the left and the right side
with a 4-minute interval
Control: sham stimulation
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Velasco 2000 (Continued)
Outcomes (1) Seizure frequency reduction
(2) Adverse events (open questions (not systematically) and physical examination - spon-
taneous reporting; postoperative MRI)
Notes Medtronic Inc. (Minneapolis, MN) donated the neurostimulators for the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “patients entered into a double-
blind protocol”
Personal communication: random selec-
tion of a folded paper (with a number on
it) out of a box by the patient, who did not
know the meaning of the number
Allocation concealment (selection bias) Low risk Personal communication: the folded paper
was randomly selected by the patient, who
did not know the meaning of number (i.e.
if it corresponded to switching stimulation
OFF between months 6 and 9 or between
months 9 and 12)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “patients entered into a double-
blind protocol”; “because neither the pa-
tient nor the examiner could determine
when the stimulator was OFF, the double-
blind protocol was considered valid”
Personal communication: only an EEG
technicianwhowas not involved in treating
or evaluating the patients knew the stimu-
lation status
Comment: although the blinding proce-
dure seems adequate, performance bias
may exist as the double-blind stimulation
OFF periods were compared to the 3-
month periods preceding them (stimula-
tion ON in all patients, but double-blind
in only half of patients!) instead of consis-
tently comparing to the double-blind stim-
ulation ON periods
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: see above, as outcome was as-
sessed by the patient and the treating physi-
cian
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Velasco 2000 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: despite good initial seizure con-
trol, neurostimulators were explanted in 2/
15 patients originally included in the study
due to skin erosions along the internalized
stimulation system; however, this occurred
before the patients entered the randomized
phase
Selective reporting (reporting bias) Unclear risk Comment 1: no evidence of selective re-
porting, but no protocol available
Comment 2: although there is no evidence
of selective reporting, authors reported
their findings incompletely: exact figures of
seizure frequency (reduction) were not re-
ported and are no longer readily available
(personal communication), which prevents
inclusion into themeta-analysis (the results
were only presented in graphs in the origi-
nal article)
Outlasting effect due to prior stimulation Unclear risk Comment: cross-over protocol with 6 to 9
months of stimulation before the random-
ized phase and without washout period
Anti-epileptic drug policy Low risk Quote: “anticonvulsive medication re-
mained unchanged and anticonvulsive
blood levels were repeated every 3 to 6
months throughout the study”
Velasco 2005
Methods Double-blind, parallel-group randomized controlled trial
• a 3-month baseline period
• implantation of the electrodes
• sham (= OFF) stimulation during the first postoperative month
• a 3-month randomized double-blind phase during which three patients received
cerebellar stimulation and two did not
• stimulation ON (unblinded) in all patients after the fourth month after
implantation (21 months)
Participants n=5, 80% male, mean age 26.0 years (range 16-35 y), duration of epilepsy ranged from
11 to 27 years
three patients had generalized epilepsy and two patients (multi)focal epilepsy of frontal
origin; all patients suffered from generalized tonic-clonic seizures, 4/5 patients also had
tonic seizures, 2/5 had drop attacks and 1/5 had myoclonic seizures / atypical absences
mean baseline seizure frequency of 14.1 (SD 6.2) seizures per month (generalized tonic-
clonic seizures 6.3 (SD 3.1))
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Velasco 2005 (Continued)
Interventions Active: bilateral stimulation of the superomedial surface of the cerebellum
• stimulation intensity of 3.8 mA, which was equivalent to a charge density of 2.0
µC/cm²/phase (the voltage needed for this was calculated at each visit by measuring the
electrodes’ impedance)
• stimulation frequency of 10 Hz
• pulse width of 450 µsec
• monopolar stimulation turned ON for 4 min alternating with 4 min OFF
Control: sham stimulation
Outcomes (1) Proportion of participants who were seizure-free
(2) Proportion of participants with a ≥ 50% seizure frequency reduction (responder
rate)
(3) Seizure frequency reduction
(4) Adverse events (standard open questions, postoperative CT scan or MRI)
Notes Medtronic Inc. (Minneapolis, MN) supported the study by providing the cerebellar
stimulation systems
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “the procedure used for randomi-
sation was to assign patients a lottery num-
ber”
Personal communication: random selec-
tion of a folded paper (with a number on
it) out of a box by the patient, who did not
know the meaning of the number
Allocation concealment (selection bias) Low risk Personal communication: the folded paper
was randomly selected by the patient, who
did not know the meaning of number (i.e.
if it corresponded to ON or OFF)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “both patients and the evaluator
were blinded with regard to whether the
stimulator was ON or OFF, a different
investigator manipulated the stimulation
code”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: see above
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: all patients completed the dou-
ble-blind randomized phase and all data
were available
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Velasco 2005 (Continued)
Selective reporting (reporting bias) Unclear risk Comment: no evidence of selective report-
ing, but no protocol available
Outlasting effect due to prior stimulation Low risk Comment: parallel-group design, no stim-
ulation prior to the randomized double-
blind phase
Anti-epileptic drug policy Low risk Quote: “All patients but one contin-
ued baseline AEDs throughout the study.
Phenytoin was reduced from 300 to 200
mg per day in case 5 because of drug in-
tolerance. Seizure decreases were not likely
to be due to AEDs, because they were not
modified.”
Personal communication: phenytoin dose
reduction in case 5 was at the seventh
month of the study
Comment: AEDswere not changed during
the randomized double-blind phase of the
trial
Velasco 2007
Methods Double-blind, parallel-group, randomized controlled trial
• 3-month baseline period
• electrode implantation
• 1-month double blind randomized phase (stimulator ON or OFF)
• long-term follow-up (range 18-84 months) with stimulation ON in all patients
Participants n=9, 66% male, mean age 29.1 years (range 14-43 y), duration of epilepsy ranged from
3 to 37 years
intractable temporal lobe epilepsy patients, poor surgery candidates (bilateral indepen-
dent foci (n=4), unilateral focus (n=3), lateralization not completely clear (n=2)); neu-
roimaging: normal MRI (n=5), left (n=3) or bilateral (n=1) hippocampal sclerosis; 6
patients had mild memory impairment in neuropsychological tests, three had severe ab-
normalities
mean baseline seizure frequency of 37.9 (SD 16.8) seizures per month
Interventions Active: uni- or bilateral hippocampal stimulation (according to seizure focus)
• stimulation amplitude of 300 µA (= 50% of the amplitude needed to obtain
electrocortical responses)
• stimulation frequency of 130 Hz
• pulse width of 450 µsec
• cyclic bipolar stimulation with 1-min trains with a 4 min interstimulus interval;
in case of bilateral stimulation: alternating 1-min stimulation on one side with a 4-min
interval between right and left sides
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Velasco 2007 (Continued)
Outcomes (1) Proportion of participants who were seizure-free
(2) Proportion of participants with a ≥ 50% seizure frequency reduction (responder
rate)
(3) Seizure frequency reduction
(4) Adverse events (open questions (not systematically) - spontaneous reporting; post-
operative MRI)
Notes no statement concerning external support
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “an aleatory (randomized by lottery
number) double-blind maneuver”
Personal communication: a non see-
through box with small folded pieces of pa-
per (with a code on it) within it, out of
which one was randomly taken by the pa-
tient who did not know the meaning of the
code
Allocation concealment (selection bias) Low risk Personal communication: “folded papers in
a non see-through box” and the aleatory
manoeuvre was performed by the patient
who did not know the meaning of the code
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind”; “because the stim-
ulation at the therapeutic stimulation pa-
rameters induced no subjective or objective
sensation, the double-blind maneuver was
considered valid”
Personal communication: the only person
who knew if the stimulation was ON or
OFF was an EEG technician who was not
involved in other parts of the study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: see above
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no data missing or patients ex-
cluded from analyses
Selective reporting (reporting bias) Unclear risk Comment:
- exact figures of seizure frequency with
stimulation ON during the blinded period
were not reported (only graphs of individ-
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Velasco 2007 (Continued)
ual patient data, fromwhich one could esti-
mate these exact figures). We consider this
more as incomplete rather than selective re-
porting. The authors provided us these data
upon our request
- no evidence of selective reporting, but no
protocol available
Outlasting effect due to prior stimulation Low risk Parallel-group design, no stimulation prior
to the randomized phase
Anti-epileptic drug policy Low risk Quote: anti-epileptic drug therapy was
maintained with no modifications during
follow-up
Wright 1984
Methods Double-blind, cross-over randomized controlled study
• electrode implantation
• the first phase of the trial was begun several months after implantation when the
individual had returned to his or her preoperative seizure frequency
• a 6-month double-blind randomized phase, consisting of three 2-month periods
(continuous, contingent and sham stimulation)
Participants n=12, 83% male, mean age 30 years (range 20-38 y), duration of epilepsy ranged from
10 to 32 years
type of epilepsy not reported, 5/12 patients had only generalized seizures, 1/12 only
partial seizures, 4/12 partial and generalized seizures, 2/12 dd complex partial seizures
versus complex absences; in addition it was reported that the EEG in each case contained
quantifiable generalized paroxysmal activity, but six patients showed additional focal
activity in the frontal or temporal regions, all patients had an IQ of ≥ 80
mean seizure frequency during sham stimulation: 61.7 (SD 53.3) seizures per month
Interventions Electrode pads were placed on the upper surface of the cerebellum, positioned parasagit-
tally approximately 2 cm from the midline on each side; stimulation parameters were:
• stimulation amplitude: 7 mA in 8/12 patients (default), 5 mA in 3/12 patients (in
2/3 because 7 mA could be detected by the patients), 7 mA (one side) and 1 mA (other
side) due to technical reasons in 1/12 patients
• stimulation frequency 10 Hz (default); 200 Hz (5 mA) in one patient because he
showed reduction in the amplitude of somatosensory evoked potentials during one
recording session after bursts of stimulation with these parameters
• pulse width not reported
• bipolar stimulation
Treatment 1: continuous stimulation
• continuous stimulation alternating from one cerebellar hemisphere to the other
every minute
Treatment 2: contingent (responsive) stimulation
• intermittent contingent stimulation of both cerebellar hemispheres occurred
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Wright 1984 (Continued)
whilst the “seizure button” on the transmitter was depressed (during an aura or seizure)
and for two minutes after it was released
Control: sham stimulation
Outcomes (1) Proportion of participants who were seizure-free
(2) Proportion of participants with a ≥ 50% seizure frequency reduction (responder
rate)
(3) Seizure frequency reduction
(4) Adverse events
(5) Neuropsychological outcome (’psychometry’)
(6) ’Proxy’ of quality of life (patients’ impressions on cerebellar stimulation)
Notes Baseline seizure frequency was not reported, changes in seizure frequency are therefore
expressed relative to the sham stimulation phase; no statement concerning external sup-
port
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “the sequence of the phaseswas ran-
domly allocated”
Allocation concealment (selection bias) Unclear risk Quote: “the sequence of the phaseswas ran-
domly allocated”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind”; “the sequence of
the phases was randomly allocated and the
codewas not broken until the trial had been
completed”; “stimulation was set at stimu-
lation parameters that couldn’t be detected
by the patients”; “before surgery and at the
end of each phase of the trial, each patient
was assessed clinically by two independent
consultant neurologists who were not in-
volved in the trial or the patient’s routine
management”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: see above
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: seizure frequency during the
three phases was not fully quantifiable in
3/12 patients (reasons: 1) one patient be-
came uncooperative; 2) one patient mislaid
some of his records; 3) one patient suffered
prolonged periods of confusion associated
with absence attacks and myoclonic jerks
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Wright 1984 (Continued)
which were difficult to quantify); however,
this was the case for each phase of the study;
moreover, the evolution of the seizure fre-
quency during the three phases of the trial
was qualitatively described
Selective reporting (reporting bias) Unclear risk Quote: “psychometry did not reveal any
major changes in any patients in any of the
phases of the trial”
Comment: no exact figures were provided,
probably because there was too much data
for publication in the journal article (rather
incomplete than selective reporting)
Comment: no evidence of selective report-
ing concerning the other outcomes, but no
protocol available
Outlasting effect due to prior stimulation Unclear risk Comment: cross-over design without a
washout period between the different treat-
ment phases
Anti-epileptic drug policy Low risk Quote: “at the time of admission to the
trial they were considered to be on the
best combination of anticonvulsants at op-
timumdosage and this dosage had not been
changed during the previous six months”
Comment: although it was not stated
explicitly, it seems unlikely that the
antiepileptic drug regimen was changed
during the trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Anderson 2008 4/7 patients not in a randomized controlled trial; 3/7 patients participated in a randomized trial but no information
about outcomes relevant to this study; additionally patients were also included in a large randomized controlled
trial already included in this review (Morrell 2011)
Andrade 2006 not a randomized controlled trial
Hodaie 2002 not a randomized controlled trial
Lim 2007 not a randomized controlled trial
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Characteristics of studies awaiting assessment [ordered by study ID]
Valentin 2012
Methods ’Single-blind within-subject control study’
Participants n=11, 73% male, mean age 37 years (range 18-51 y)
refractory epilepsy patients: 6 patients had symptomatic generalized epilepsy, 5 had frontal lobe epilepsy; 6 patients
had previously been treated with vagus nerve stimulation
Interventions centromedian thalamic deep brain stimulation
Outcomes outcome measures include seizure freedom, responder rate and quality of life (and possibly other outcomes)
Notes Abstract was presented at the 10th European Congress on Epileptology (London, United Kingdom; September-
October 2012) and published in Epilepsia 53 Suppl 5. Unclear to what extent the trial meets this review’s eligibility
criteria (randomized controlled trial?). However, we expect the trial to published as a journal article soon and if
applicable it will be included in the first update of this review
van Rijckevorsel 2004
Methods
Participants
Interventions
Outcomes
Notes A randomized controlled trial evaluating the efficacy and safety of DBS of the mammillary bodies and mammillotha-
lamic tracts was announced but results have not been published yet; authors were contacted but results could not be
provided yet
Characteristics of ongoing studies [ordered by study ID]
Boon 2007b
Trial name or title Prospective Randomized Controlled Study of Neurostimulation in the Medial Temporal Lobe for Patients
With Medically Refractory Medial Temporal Lobe Epilepsy: Controlled Randomized Stimulation Versus
Resection (CoRaStiR)
Methods Prospective, multicentre, parallel-group, single-blind (subject) randomized controlled trial
Participants Presurgical candidates with pharmacoresistant partial seizures despite optimal medical treatment and history
of temporal lobe epilepsy
Video-EEG characteristics showing temporal lobe seizure onset (left-sided or right-sided seizure onset) in at
least one recorded habitual seizure
Presence of a structural abnormality in the medial temporal lobe, suggestive of hippocampal sclerosis as
evidenced by optimum MRI
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Boon 2007b (Continued)
Age ≥ 18 years
Total IQ > 80
Interventions Group 1: electrode implantation in the medial temporal lobe and immediate unilateral hippocampal neu-
rostimulation (12 months)
Group 2: electrode implantation in the medial temporal lobe but unilateral hippocampal neurostimulation
(6 months) is delayed for 6 months
Group 3: amygdalohippocampectomy
Outcomes (1) Proportion of participants with a ≥ 50% seizure frequency reduction (responder rate)
(2) Seizure frequency reduction
(3) Adverse events
(4) Neuropsychological outcome
(5) Quality of life (QOLIE 89)
Starting date June 2007
Contact information Kristl Vonck, MD, PhD - Ghent University, Belgium - kristl.vonck@UGent.be
Notes Currently still recruiting participants (August 2013)
Sponsored by Medtronics
Chabardes 2005
Trial name or title Assessment of Subthalamic Nucleus Stimulation in Drug Resistant Epilepsy Associated With Dopaminergic
Metabolism Deficit. A Randomized, Double Blind, Controlled Trial
Methods Double-blind (subject, investigator, outcome assessor), randomized controlled clinical trial with two cross-
over groups
Participants Epilepsy resistant to AEDs and dopaminergic D2-agonist
Curative resective surgery not possible
Metabolism deficiency of DOPA above 1 DS, evaluated by Positron Emission Tomography (PET) using
fluorodopa
Age ranging from 18 to 50
Interventions Group 1: 3 months high-frequency stimulation of the subthalamic nucleus followed by 3 months SHAM
stimulation
Group 2: 3 months SHAM stimulation followed by 3 months high-frequency stimulation of the subthalamic
nucleus
Outcomes (1) Proportion of participants with a ≥ 50% seizure frequency reduction (responder rate)
(2) Seizure frequency reduction
(3) Adverse events
(4) Neuropsychological outcome (WAIS, GROBER and Busckhe, Wisconsin Card Sorting Test, TRAIL test,
LURIA test, Beck Depression Inventory, verbal flow test, empathy test)
(5) Quality of life (SEALS, QOLIE-31 and NHP scales)
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Chabardes 2005 (Continued)
Starting date September 2005
Contact information Stephan Chabardes, MD - University Hospital of Grenoble, France
Notes The study has been preliminary terminated in March 2010. If the available results will not be published by
the first update of this review, authors will be contacted
Wiebe 2008
Trial name or title Medical vs Electrical Therapy for Temporal Lobe Epilepsy (METTLE)
Methods Multicentre parallel-group, double-blind (subject, caregiver, investigator and outcome assessor) randomized
controlled trial
Participants Adults with refractory uni- or bilateral mesial temporal lobe epilepsy (failure of ≥ 2 AEDs)
Patient preference for non-resective surgery, or not a candidate for mesial temporal resection
Global IQ ≥70
Interventions Experimental group: uni- or bilateral hippocampal stimulation for 6 months
Control group: uni- or bilateral hippocampal SHAM stimulation for 6 months
Outcomes (1) Seizure frequency reduction
(2) Adverse events
(3) Neuropsychological outcome
(4) Quality of life
Starting date January 2008
Contact information Samuel Wiebe, MD - University of Calgary, Canada - swiebe@ucalgary.ca
Notes The study has been preliminary terminated in March 2012. If the available results will not be published by
the first update of this review, authors will be contacted
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D A T A A N D A N A L Y S E S
Comparison 1. Stimulation versus sham stimulation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Seizure freedom 9 Odds Ratio (Fixed, 95% CI) Subtotals only
1.1 Anterior thalamic nucleus 1 109 Odds Ratio (Fixed, 95% CI) 0.33 [0.01, 8.36]
1.2 Centromedian thalamic
stimulation
1 12 Odds Ratio (Fixed, 95% CI) 1.0 [0.11, 9.39]
1.3 Cerebellar stimulation 3 33 Odds Ratio (Fixed, 95% CI) 0.96 [0.22, 4.12]
1.4 Hippocampal stimulation 3 21 Odds Ratio (Fixed, 95% CI) 1.03 [0.21, 5.15]
1.5 Closed-loop ictal onset
zone stimulation
1 191 Odds Ratio (Fixed, 95% CI) 4.95 [0.23, 104.44]
2 Responder rate 9 Odds Ratio (Fixed, 95% CI) Subtotals only
2.1 Anterior thalamic nucleus 1 108 Odds Ratio (Fixed, 95% CI) 1.20 [0.52, 2.80]
2.2 Centromedian thalamic
stimulation
1 12 Odds Ratio (Fixed, 95% CI) 1.0 [0.27, 3.69]
2.3 Cerebellar stimulation 3 33 Odds Ratio (Fixed, 95% CI) 2.43 [0.46, 12.84]
2.4 Hippocampal stimulation 3 21 Odds Ratio (Fixed, 95% CI) 1.20 [0.36, 4.01]
2.5 Closed-loop ictal onset
zone stimulation
1 191 Odds Ratio (Fixed, 95% CI) 1.12 [0.59, 2.11]
3 Seizure frequency reduction 9 Mean Difference (Fixed, 95% CI) Subtotals only
3.1 Anterior thalamic nucleus
stimulation
1 108 Mean Difference (Fixed, 95% CI) -17.44 [-32.53, -2.
35]
3.2 Centromedian thalamic
stimulation
1 12 Mean Difference (Fixed, 95% CI) 7.05 [-44.05, 58.15]
3.3 Cerebellar stimulation 3 33 Mean Difference (Fixed, 95% CI) -12.37 [-35.30, 10.
55]
3.4 Hippocampal stimulation 3 21 Mean Difference (Fixed, 95% CI) -28.14 [-34.09, -22.
19]
3.5 Closed-loop ictal onset
zone stimulation
1 191 Mean Difference (Fixed, 95% CI) -24.95 [-42.00, -7.
90]
4 Quality of Life 3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 Anterior thalamic nucleus
stimulation
1 105 Mean Difference (IV, Fixed, 95% CI) -0.30 [-3.50, 2.90]
4.2 Hippocampal stimulation 1 6 Mean Difference (IV, Fixed, 95% CI) -3.00 [-53.25, 43.
25]
4.3 Closed-loop ictal onset
zone stimulation
1 180 Mean Difference (IV, Fixed, 95% CI) -0.14 [-2.88, 2.60]
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Comparison 2. Stimulation versus sham stimulation - sensitivity analyses
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Seizure freedom RR 9 Risk Ratio (Fixed, 95% CI) Subtotals only
1.1 Anterior thalamic nucleus 1 109 Risk Ratio (Fixed, 95% CI) 0.34 [0.01, 8.15]
1.2 Centromedian thalamic
stimulation
1 12 Risk Ratio (Fixed, 95% CI) 1.0 [0.14, 7.10]
1.3 Cerebellar stimulation 3 33 Risk Ratio (Fixed, 95% CI) 0.96 [0.26, 3.52]
1.4 Hippocampal stimulation 3 21 Risk Ratio (Fixed, 95% CI) 1.03 [0.25, 4.19]
1.5 Closed-loop ictal onset
zone stimulation
1 191 Risk Ratio (Fixed, 95% CI) 4.85 [0.24, 99.64]
2 Responder rate RR 9 Risk Ratio (Fixed, 95% CI) Subtotals only
2.1 Anterior thalamic nucleus 1 108 Risk Ratio (Fixed, 95% CI) 1.14 [0.62, 2.10]
2.2 Centromedian thalamic
stimulation
1 12 Risk Ratio (Fixed, 95% CI) 1.0 [0.38, 2.66]
2.3 Cerebellar stimulation 3 33 Risk Ratio (Fixed, 95% CI) 2.00 [0.51, 7.86]
2.4 Hippocampal stimulation 3 21 Risk Ratio (Fixed, 95% CI) 1.12 [0.47, 2.66]
2.5 Closed-loop ictal onset
zone stimulation
1 191 Risk Ratio (Fixed, 95% CI) 1.09 [0.69, 1.72]
3 Seizure freedom OR 0.25 9 Odds Ratio (Fixed, 95% CI) Subtotals only
3.1 Anterior thalamic nucleus 1 109 Odds Ratio (Fixed, 95% CI) 0.20 [0.00, 15.17]
3.2 Centromedian thalamic
stimulation
1 12 Odds Ratio (Fixed, 95% CI) 1.0 [0.05, 19.79]
3.3 Cerebellar stimulation 3 33 Odds Ratio (Fixed, 95% CI) 0.96 [0.13, 6.83]
3.4 Hippocampal stimulation 3 21 Odds Ratio (Fixed, 95% CI) 1.03 [0.13, 8.41]
3.5 Closed-loop ictal onset
zone stimulation
1 191 Odds Ratio (Fixed, 95% CI) 8.91 [0.14, 560.31]
4 Responder rate OR 0.25 9 Odds Ratio (Fixed, 95% CI) Subtotals only
4.1 Anterior thalamic nucleus 1 108 Odds Ratio (Fixed, 95% CI) 1.20 [0.52, 2.80]
4.2 Centromedian thalamic
stimulation
1 12 Odds Ratio (Fixed, 95% CI) 1.0 [0.31, 3.24]
4.3 Cerebellar stimulation 3 33 Odds Ratio (Fixed, 95% CI) 2.98 [0.39, 22.77]
4.4 Hippocampal stimulation 3 21 Odds Ratio (Fixed, 95% CI) 1.15 [0.35, 3.77]
4.5 Closed-loop ictal onset
zone stimulation
1 191 Odds Ratio (Fixed, 95% CI) 1.12 [0.59, 2.11]
5 Seizure freedom RR 0.25 9 Risk Ratio (Fixed, 95% CI) Subtotals only
5.1 Anterior thalamic nucleus 1 109 Risk Ratio (Fixed, 95% CI) 0.21 [0.00, 14.95]
5.2 Centromedian thalamic
stimulation
1 12 Risk Ratio (Fixed, 95% CI) 1.0 [0.06, 15.99]
5.3 Cerebellar stimulation 3 33 Risk Ratio (Fixed, 95% CI) 0.96 [0.15, 6.04]
5.4 Hippocampal stimulation 3 21 Risk Ratio (Fixed, 95% CI) 1.02 [0.16, 6.46]
5.5 Closed-loop ictal onset
zone stimulation
1 191 Risk Ratio (Fixed, 95% CI) 8.72 [0.14, 538.18]
6 Responder rate RR 0.25 9 Risk Ratio (Fixed, 95% CI) Subtotals only
6.1 Anterior thalamic nucleus 1 108 Risk Ratio (Fixed, 95% CI) 1.14 [0.62, 2.10]
6.2 Centromedian thalamic
stimulation
1 12 Risk Ratio (Fixed, 95% CI) 1.0 [0.40, 2.52]
6.3 Cerebellar stimulation 3 33 Risk Ratio (Fixed, 95% CI) 2.28 [0.40, 13.02]
6.4 Hippocampal stimulation 3 21 Risk Ratio (Fixed, 95% CI) 1.08 [0.46, 2.55]
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6.5 Closed-loop ictal onset
zone stimulation
1 191 Risk Ratio (Fixed, 95% CI) 1.09 [0.69, 1.72]
Analysis 1.1. Comparison 1 Stimulation versus sham stimulation, Outcome 1 Seizure freedom.
Review: Deep brain and cortical stimulation for epilepsy
Comparison: 1 Stimulation versus sham stimulation
Outcome: 1 Seizure freedom
Study or subgroup Stimulation Control log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Anterior thalamic nucleus
Fisher 2010 54 55 -1.0986 (1.6442) 100.0 % 0.33 [ 0.01, 8.36 ]
Subtotal (95% CI) 54 55 100.0 % 0.33 [ 0.01, 8.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
2 Centromedian thalamic stimulation
Fisher 1992 6 6 0 (1.1429) 100.0 % 1.00 [ 0.11, 9.39 ]
Subtotal (95% CI) 6 6 100.0 % 1.00 [ 0.11, 9.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Cerebellar stimulation
Van Buren 1978 5 5 0 (1.1667) 40.6 % 1.00 [ 0.10, 9.84 ]
Velasco 2005 3 2 -0.3365 (2.1647) 11.8 % 0.71 [ 0.01, 49.71 ]
Wright 1984 9 9 0 (1.0769) 47.6 % 1.00 [ 0.12, 8.25 ]
Subtotal (95% CI) 17 16 100.0 % 0.96 [ 0.22, 4.12 ]
Heterogeneity: Chi2 = 0.02, df = 2 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
4 Hippocampal stimulation
McLachlan 2010 2 2 0 (1.3333) 37.9 % 1.00 [ 0.07, 13.64 ]
Tellez-Zenteno 2006 4 4 0 (1.2) 46.8 % 1.00 [ 0.10, 10.51 ]
Velasco 2007 4 5 0.2007 (2.0986) 15.3 % 1.22 [ 0.02, 74.73 ]
Subtotal (95% CI) 10 11 100.0 % 1.03 [ 0.21, 5.15 ]
Heterogeneity: Chi2 = 0.01, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
5 Closed-loop ictal onset zone stimulation
Morrell 2011 97 94 1.5989 (1.556) 100.0 % 4.95 [ 0.23, 104.44 ]
Subtotal (95% CI) 97 94 100.0 % 4.95 [ 0.23, 104.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Chi2 = 1.50, df = 4 (P = 0.83), I2 =0.0%
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Analysis 1.2. Comparison 1 Stimulation versus sham stimulation, Outcome 2 Responder rate.
Review: Deep brain and cortical stimulation for epilepsy
Comparison: 1 Stimulation versus sham stimulation
Outcome: 2 Responder rate
Study or subgroup Stimulation Control log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Anterior thalamic nucleus
Fisher 2010 54 54 0.1848 (0.4304) 100.0 % 1.20 [ 0.52, 2.80 ]
Subtotal (95% CI) 54 54 100.0 % 1.20 [ 0.52, 2.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
2 Centromedian thalamic stimulation
Fisher 1992 6 6 0 (0.6667) 100.0 % 1.00 [ 0.27, 3.69 ]
Subtotal (95% CI) 6 6 100.0 % 1.00 [ 0.27, 3.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Cerebellar stimulation
Van Buren 1978 5 5 0 (1.7678) 23.1 % 1.00 [ 0.03, 31.97 ]
Velasco 2005 3 2 2.1203 (1.8619) 20.8 % 8.33 [ 0.22, 320.40 ]
Wright 1984 9 9 0.7985 (1.1328) 56.2 % 2.22 [ 0.24, 20.47 ]
Subtotal (95% CI) 17 16 100.0 % 2.43 [ 0.46, 12.84 ]
Heterogeneity: Chi2 = 0.70, df = 2 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.29)
4 Hippocampal stimulation
McLachlan 2010 2 2 0 (1.3333) 21.2 % 1.00 [ 0.07, 13.64 ]
Tellez-Zenteno 2006 4 4 0 (0.75) 66.8 % 1.00 [ 0.23, 4.35 ]
Velasco 2007 4 5 1.5506 (1.7704) 12.0 % 4.71 [ 0.15, 151.49 ]
Subtotal (95% CI) 10 11 100.0 % 1.20 [ 0.36, 4.01 ]
Heterogeneity: Chi2 = 0.68, df = 2 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.76)
5 Closed-loop ictal onset zone stimulation
Morrell 2011 97 94 0.1133 (0.3236) 100.0 % 1.12 [ 0.59, 2.11 ]
0.02 0.1 1 10 50
Favours control Favours stimulation
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(. . . Continued)
Study or subgroup Stimulation Control log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 97 94 100.0 % 1.12 [ 0.59, 2.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Chi2 = 0.81, df = 4 (P = 0.94), I2 =0.0%
0.02 0.1 1 10 50
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Analysis 1.3. Comparison 1 Stimulation versus sham stimulation, Outcome 3 Seizure frequency reduction.
Review: Deep brain and cortical stimulation for epilepsy
Comparison: 1 Stimulation versus sham stimulation
Outcome: 3 Seizure frequency reduction
Study or subgroup Experimental Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Anterior thalamic nucleus stimulation
Fisher 2010 (1) 54 54 -17.44 (7.7) 100.0 % -17.44 [ -32.53, -2.35 ]
Subtotal (95% CI) 54 54 100.0 % -17.44 [ -32.53, -2.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.26 (P = 0.024)
2 Centromedian thalamic stimulation
Fisher 1992 6 6 7.05 (26.07) 100.0 % 7.05 [ -44.05, 58.15 ]
Subtotal (95% CI) 6 6 100.0 % 7.05 [ -44.05, 58.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
3 Cerebellar stimulation
Van Buren 1978 5 5 -7.12 (31.3) 14.0 % -7.12 [ -68.47, 54.23 ]
Velasco 2005 3 2 -36.7 (29.51) 15.7 % -36.70 [ -94.54, 21.14 ]
Wright 1984 9 9 -7.98 (13.95) 70.3 % -7.98 [ -35.32, 19.36 ]
Subtotal (95% CI) 17 16 100.0 % -12.37 [ -35.30, 10.55 ]
-100 -50 0 50 100
Favours stimulation Favours control
mentioned in the text. These correct values are -17.4% with 95% CI [-31.2;-1.0] for Fisher 2010 and -24.9% with 95% CI [-40.1;-6.0] for Morrell 2011.
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Study or subgroup Experimental Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
Heterogeneity: Chi2 = 0.81, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.06 (P = 0.29)
4 Hippocampal stimulation
McLachlan 2010 2 2 -28.13 (3.13) 94.1 % -28.13 [ -34.26, -22.00 ]
Tellez-Zenteno 2006 4 4 -20.32 (13.84) 4.8 % -20.32 [ -47.45, 6.81 ]
Velasco 2007 4 5 -63.2 (29.01) 1.1 % -63.20 [ -120.06, -6.34 ]
Subtotal (95% CI) 10 11 100.0 % -28.14 [ -34.09, -22.19 ]
Heterogeneity: Chi2 = 1.78, df = 2 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 9.27 (P < 0.00001)
5 Closed-loop ictal onset zone stimulation
Morrell 2011 97 94 -24.95 (8.7) 100.0 % -24.95 [ -42.00, -7.90 ]
Subtotal (95% CI) 97 94 100.0 % -24.95 [ -42.00, -7.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.87 (P = 0.0041)
Test for subgroup differences: Chi2 = 4.67, df = 4 (P = 0.32), I2 =14%
-100 -50 0 50 100
Favours stimulation Favours control
mentioned in the text. These correct values are -17.4% with 95% CI [-31.2;-1.0] for Fisher 2010 and -24.9% with 95% CI [-40.1;-6.0] for Morrell 2011.
(1) Fisher 2010 (anterior thalamic nucleus stimulation) and Morrell 2011 (closed-loop ictal onset zone stimulation) estimated the treatment effect and its standard error
on a logarithmic
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Analysis 1.4. Comparison 1 Stimulation versus sham stimulation, Outcome 4 Quality of Life.
Review: Deep brain and cortical stimulation for epilepsy
Comparison: 1 Stimulation versus sham stimulation
Outcome: 4 Quality of Life
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Anterior thalamic nucleus stimulation
Fisher 2010 (1) 52 2.5 (8.7) 53 2.8 (8) 100.0 % -0.30 [ -3.50, 2.90 ]
Subtotal (95% CI) 52 53 100.0 % -0.30 [ -3.50, 2.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.85)
2 Hippocampal stimulation
Tellez-Zenteno 2006 3 55 (33) 3 60 (27) 100.0 % -5.00 [ -53.25, 43.25 ]
Subtotal (95% CI) 3 3 100.0 % -5.00 [ -53.25, 43.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
3 Closed-loop ictal onset zone stimulation
Morrell 2011 93 2.04 (9.43) 87 2.18 (9.35) 100.0 % -0.14 [ -2.88, 2.60 ]
Subtotal (95% CI) 93 87 100.0 % -0.14 [ -2.88, 2.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Chi2 = 0.04, df = 2 (P = 0.98), I2 =0.0%
-50 -25 0 25 50
Favours control Favours stimulation
table. Improvements of 5-11.7 have been defined in literature (Borghs 2012; Cramer 2004; Wiebe 2002) as being clinically meaningful, positive is better.
(1) To measure quality of life, Tellez-Zenteno 2006 and Morrell 2006 used the QOLIE-89 questionnaire, whereas Fisher 2010 used the QOLIE-31 questionnaire (=
abbreviated form of the QOLIE-89
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Analysis 2.1. Comparison 2 Stimulation versus sham stimulation - sensitivity analyses, Outcome 1 Seizure
freedom RR.
Review: Deep brain and cortical stimulation for epilepsy
Comparison: 2 Stimulation versus sham stimulation - sensitivity analyses
Outcome: 1 Seizure freedom RR
Study or subgroup Experimental Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Anterior thalamic nucleus
Fisher 2010 54 55 -1.0806 (1.6219) 100.0 % 0.34 [ 0.01, 8.15 ]
Subtotal (95% CI) 54 55 100.0 % 0.34 [ 0.01, 8.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.51)
2 Centromedian thalamic stimulation
Fisher 1992 6 6 0 (1) 100.0 % 1.00 [ 0.14, 7.10 ]
Subtotal (95% CI) 6 6 100.0 % 1.00 [ 0.14, 7.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Cerebellar stimulation
Van Buren 1978 5 5 0 (1) 43.6 % 1.00 [ 0.14, 7.10 ]
Velasco 2005 3 2 -0.288 (1.8484) 12.8 % 0.75 [ 0.02, 28.07 ]
Wright 1984 9 9 0 (1) 43.6 % 1.00 [ 0.14, 7.10 ]
Subtotal (95% CI) 17 16 100.0 % 0.96 [ 0.26, 3.52 ]
Heterogeneity: Chi2 = 0.02, df = 2 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.96)
4 Hippocampal stimulation
McLachlan 2010 2 2 0 (1.2247) 34.3 % 1.00 [ 0.09, 11.03 ]
Tellez-Zenteno 2006 4 4 0 (1) 51.5 % 1.00 [ 0.14, 7.10 ]
Velasco 2007 4 5 0.1823 (1.9061) 14.2 % 1.20 [ 0.03, 50.31 ]
Subtotal (95% CI) 10 11 100.0 % 1.03 [ 0.25, 4.19 ]
Heterogeneity: Chi2 = 0.01, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
5 Closed-loop ictal onset zone stimulation
Morrell 2011 97 94 1.5783 (1.5425) 100.0 % 4.85 [ 0.24, 99.64 ]
Subtotal (95% CI) 97 94 100.0 % 4.85 [ 0.24, 99.64 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Chi2 = 1.49, df = 4 (P = 0.83), I2 =0.0%
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Analysis 2.2. Comparison 2 Stimulation versus sham stimulation - sensitivity analyses, Outcome 2
Responder rate RR.
Review: Deep brain and cortical stimulation for epilepsy
Comparison: 2 Stimulation versus sham stimulation - sensitivity analyses
Outcome: 2 Responder rate RR
Study or subgroup Experimental Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Anterior thalamic nucleus
Fisher 2010 54 54 0.1335 (0.3113) 100.0 % 1.14 [ 0.62, 2.10 ]
Subtotal (95% CI) 54 54 100.0 % 1.14 [ 0.62, 2.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
2 Centromedian thalamic stimulation
Fisher 1992 6 6 0 (0.5) 100.0 % 1.00 [ 0.38, 2.66 ]
Subtotal (95% CI) 6 6 100.0 % 1.00 [ 0.38, 2.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Cerebellar stimulation
Van Buren 1978 5 5 0 (1.4142) 24.4 % 1.00 [ 0.06, 15.99 ]
Velasco 2005 3 2 1.3218 (1.3478) 26.8 % 3.75 [ 0.27, 52.64 ]
Wright 1984 9 9 0.6931 (1) 48.8 % 2.00 [ 0.28, 14.20 ]
Subtotal (95% CI) 17 16 100.0 % 2.00 [ 0.51, 7.86 ]
Heterogeneity: Chi2 = 0.46, df = 2 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
4 Hippocampal stimulation
McLachlan 2010 2 2 0 (1.2247) 13.1 % 1.00 [ 0.09, 11.03 ]
Tellez-Zenteno 2006 4 4 0 (0.5) 78.4 % 1.00 [ 0.38, 2.66 ]
Velasco 2007 4 5 1.2809 (1.5166) 8.5 % 3.60 [ 0.18, 70.34 ]
Subtotal (95% CI) 10 11 100.0 % 1.12 [ 0.47, 2.66 ]
Heterogeneity: Chi2 = 0.65, df = 2 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.81)
5 Closed-loop ictal onset zone stimulation
Morrell 2011 97 94 0.0819 (0.234) 100.0 % 1.09 [ 0.69, 1.72 ]
Subtotal (95% CI) 97 94 100.0 % 1.09 [ 0.69, 1.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Chi2 = 0.76, df = 4 (P = 0.94), I2 =0.0%
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Analysis 2.3. Comparison 2 Stimulation versus sham stimulation - sensitivity analyses, Outcome 3 Seizure
freedom OR 0.25.
Review: Deep brain and cortical stimulation for epilepsy
Comparison: 2 Stimulation versus sham stimulation - sensitivity analyses
Outcome: 3 Seizure freedom OR 0.25
Study or subgroup Experimental Control log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Anterior thalamic nucleus
Fisher 2010 54 55 -1.5912 (2.1992) 100.0 % 0.20 [ 0.00, 15.17 ]
Subtotal (95% CI) 54 55 100.0 % 0.20 [ 0.00, 15.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
2 Centromedian thalamic stimulation
Fisher 1992 6 6 0 (1.523) 100.0 % 1.00 [ 0.05, 19.79 ]
Subtotal (95% CI) 6 6 100.0 % 1.00 [ 0.05, 19.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Cerebellar stimulation
Van Buren 1978 5 5 0 (1.5428) 42.2 % 1.00 [ 0.05, 20.57 ]
Velasco 2005 3 2 -0.3677 (2.9584) 11.5 % 0.69 [ 0.00, 228.30 ]
Wright 1984 9 9 0 (1.4708) 46.4 % 1.00 [ 0.06, 17.86 ]
Subtotal (95% CI) 17 16 100.0 % 0.96 [ 0.13, 6.83 ]
Heterogeneity: Chi2 = 0.01, df = 2 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
4 Hippocampal stimulation
McLachlan 2010 2 2 0 (1.6971) 39.9 % 1.00 [ 0.04, 27.83 ]
Tellez-Zenteno 2006 4 4 0 (1.5713) 46.5 % 1.00 [ 0.05, 21.75 ]
Velasco 2007 4 5 0.2113 (2.9027) 13.6 % 1.24 [ 0.00, 365.22 ]
Subtotal (95% CI) 10 11 100.0 % 1.03 [ 0.13, 8.41 ]
Heterogeneity: Chi2 = 0.00, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.98)
5 Closed-loop ictal onset zone stimulation
Morrell 2011 97 94 2.1867 (2.1132) 100.0 % 8.91 [ 0.14, 560.31 ]
Subtotal (95% CI) 97 94 100.0 % 8.91 [ 0.14, 560.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Chi2 = 1.59, df = 4 (P = 0.81), I2 =0.0%
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Analysis 2.4. Comparison 2 Stimulation versus sham stimulation - sensitivity analyses, Outcome 4
Responder rate OR 0.25.
Review: Deep brain and cortical stimulation for epilepsy
Comparison: 2 Stimulation versus sham stimulation - sensitivity analyses
Outcome: 4 Responder rate OR 0.25
Study or subgroup Experimental Control log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Anterior thalamic nucleus
Fisher 2010 54 54 0.1848 (0.4304) 100.0 % 1.20 [ 0.52, 2.80 ]
Subtotal (95% CI) 54 54 100.0 % 1.20 [ 0.52, 2.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
2 Centromedian thalamic stimulation
Fisher 1992 6 6 0 (0.6) 100.0 % 1.00 [ 0.31, 3.24 ]
Subtotal (95% CI) 6 6 100.0 % 1.00 [ 0.31, 3.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Cerebellar stimulation
Van Buren 1978 5 5 0 (1.7678) 34.5 % 1.00 [ 0.03, 31.97 ]
Velasco 2005 3 2 2.785 (2.3851) 18.9 % 16.20 [ 0.15, 1736.64 ]
Wright 1984 9 9 1.2098 (1.5204) 46.6 % 3.35 [ 0.17, 66.00 ]
Subtotal (95% CI) 17 16 100.0 % 2.98 [ 0.39, 22.77 ]
Heterogeneity: Chi2 = 0.89, df = 2 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.29)
4 Hippocampal stimulation
McLachlan 2010 2 2 0 (1.6971) 12.7 % 1.00 [ 0.04, 27.83 ]
Tellez-Zenteno 2006 4 4 0 (0.6734) 80.4 % 1.00 [ 0.27, 3.74 ]
Velasco 2007 4 5 2.089 (2.3018) 6.9 % 8.08 [ 0.09, 735.42 ]
Subtotal (95% CI) 10 11 100.0 % 1.15 [ 0.35, 3.77 ]
Heterogeneity: Chi2 = 0.77, df = 2 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
5 Closed-loop ictal onset zone stimulation
Morrell 2011 97 94 0.1133 (0.3236) 100.0 % 1.12 [ 0.59, 2.11 ]
Subtotal (95% CI) 97 94 100.0 % 1.12 [ 0.59, 2.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Chi2 = 0.90, df = 4 (P = 0.92), I2 =0.0%
0.01 0.1 1 10 100
Favours control Favours stimulation
85Deep brain and cortical stimulation for epilepsy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.5. Comparison 2 Stimulation versus sham stimulation - sensitivity analyses, Outcome 5 Seizure
freedom RR 0.25.
Review: Deep brain and cortical stimulation for epilepsy
Comparison: 2 Stimulation versus sham stimulation - sensitivity analyses
Outcome: 5 Seizure freedom RR 0.25
Study or subgroup Experimental Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Anterior thalamic nucleus
Fisher 2010 54 55 -1.5734 (2.1826) 100.0 % 0.21 [ 0.00, 14.95 ]
Subtotal (95% CI) 54 55 100.0 % 0.21 [ 0.00, 14.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
2 Centromedian thalamic stimulation
Fisher 1992 6 6 0 (1.4142) 100.0 % 1.00 [ 0.06, 15.99 ]
Subtotal (95% CI) 6 6 100.0 % 1.00 [ 0.06, 15.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Cerebellar stimulation
Van Buren 1978 5 5 0 (1.4142) 44.0 % 1.00 [ 0.06, 15.99 ]
Velasco 2005 3 2 -0.3365 (2.7045) 12.0 % 0.71 [ 0.00, 143.20 ]
Wright 1984 9 9 0 (1.4142) 44.0 % 1.00 [ 0.06, 15.99 ]
Subtotal (95% CI) 17 16 100.0 % 0.96 [ 0.15, 6.04 ]
Heterogeneity: Chi2 = 0.01, df = 2 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
4 Hippocampal stimulation
McLachlan 2010 2 2 0 (1.4142) 44.2 % 1.00 [ 0.06, 15.99 ]
Tellez-Zenteno 2006 4 4 0 (1.4142) 44.2 % 1.00 [ 0.06, 15.99 ]
Velasco 2007 4 5 0.2007 (2.7561) 11.6 % 1.22 [ 0.01, 271.12 ]
Subtotal (95% CI) 10 11 100.0 % 1.02 [ 0.16, 6.46 ]
Heterogeneity: Chi2 = 0.00, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
5 Closed-loop ictal onset zone stimulation
Morrell 2011 97 94 2.166 (2.1032) 100.0 % 8.72 [ 0.14, 538.18 ]
Subtotal (95% CI) 97 94 100.0 % 8.72 [ 0.14, 538.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Chi2 = 1.58, df = 4 (P = 0.81), I2 =0.0%
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Analysis 2.6. Comparison 2 Stimulation versus sham stimulation - sensitivity analyses, Outcome 6
Responder rate RR 0.25.
Review: Deep brain and cortical stimulation for epilepsy
Comparison: 2 Stimulation versus sham stimulation - sensitivity analyses
Outcome: 6 Responder rate RR 0.25
Study or subgroup Experimental Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Anterior thalamic nucleus
Fisher 2010 54 54 0.1335 (0.3113) 100.0 % 1.14 [ 0.62, 2.10 ]
Subtotal (95% CI) 54 54 100.0 % 1.14 [ 0.62, 2.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
2 Centromedian thalamic stimulation
Fisher 1992 6 6 0 (0.4714) 100.0 % 1.00 [ 0.40, 2.52 ]
Subtotal (95% CI) 6 6 100.0 % 1.00 [ 0.40, 2.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Cerebellar stimulation
Van Buren 1978 5 5 0 (1.4142) 39.5 % 1.00 [ 0.06, 15.99 ]
Velasco 2005 3 2 1.8608 (1.9387) 21.0 % 6.43 [ 0.14, 287.32 ]
Wright 1984 9 9 1.0986 (1.4142) 39.5 % 3.00 [ 0.19, 47.96 ]
Subtotal (95% CI) 17 16 100.0 % 2.28 [ 0.40, 13.02 ]
Heterogeneity: Chi2 = 0.66, df = 2 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
4 Hippocampal stimulation
McLachlan 2010 2 2 0 (1.4142) 9.6 % 1.00 [ 0.06, 15.99 ]
Tellez-Zenteno 2006 4 4 0 (0.4714) 86.1 % 1.00 [ 0.40, 2.52 ]
Velasco 2007 4 5 1.8101 (2.0967) 4.4 % 6.11 [ 0.10, 372.25 ]
Subtotal (95% CI) 10 11 100.0 % 1.08 [ 0.46, 2.55 ]
Heterogeneity: Chi2 = 0.71, df = 2 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.86)
5 Closed-loop ictal onset zone stimulation
Morrell 2011 97 94 0.0819 (0.234) 100.0 % 1.09 [ 0.69, 1.72 ]
Subtotal (95% CI) 97 94 100.0 % 1.09 [ 0.69, 1.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Chi2 = 0.73, df = 4 (P = 0.95), I2 =0.0%
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A P P E N D I C E S
Appendix 1. Calculation of treatment effects in Van Buren 1978
We illustrate the way we calculated treatment effects for Van Buren 1978 taking patient 2 of their trial as an example. Van Buren
1978 reported 183% seizure frequency increase during the early double-blind stimulation ON period, a 125% increase during the
late double-blind stimulation ON period, a 812% increase during the early double-blind stimulation OFF period and finally a 156%
increase during the late double-blind stimulation OFF period. This can be formulated as 283%, 225%, 912% and 256% of baseline
seizure frequency respectively. Comparing stimulation ON to stimulation OFF periods with regard to baseline seizure frequency would
result in a 330% seizure reduction with stimulation ON [(283-912+225-256)% x½]. As 4 out of 5 patients’ seizure frequency increased
during the trial (more accurate seizure detection? spontaneous evolution of their disease?), we decided to directly compare stimulation
ON to stimulation OFF periods to avoid treatment effects > 100%. For patient 2, this results into 69% (1-[283/912]) and 12% (1-
[225/256]) seizure frequency reductions during early and late double-blind evaluations respectively, or a mean 41% ([69+12)% x ½)
reduction in seizure frequency across both periods. Responders during stimulation ON periods were defined as subjects experiencing
a ≥ 50% seizure frequency reduction with regard to stimulation OFF periods (direct comparison), whereas the inverse definition was
used to define responders during stimulation OFF periods.
Appendix 2. Search strategies
1. CENTRAL search strategy
#1 MeSH descriptor Epilepsy explode all trees
#2 MeSH descriptor Seizures explode all trees
#3 epilep* OR seizure* OR convulsion*
#4 (#1 OR #2 OR #3)
#5 MeSH descriptor Deep Brain Stimulation explode all trees
#6 stimul*
#7 (#5 OR #6)
#8 (#4 AND #7)
2. PubMed search strategy
Our search strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE
(sensitivity-maximizing version, 2008 revision; Pubmed format) (Lefebvre 2011).
#1 randomized controlled trial [pt]
#2 controlled clinical trial [pt]
#3 random* [tiab]
#4 placebo [tiab]
#5 sham [tiab]
#6 trial [tiab]
#7 groups [tiab]
#8 blind* [tiab]
#9 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8)
#10 animals [mh] NOT humans [mh]
#11 (#9 NOT #10)
#12 epilepsy [MeSH]
#13 seizures [MeSH]
#14 epileps* OR epilept*
#15 seizure*
#16 convulsion*
#17 (#12 OR #13 OR #14 OR #15 OR #16)
#18 deep brain stimulation [MeSH]
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#19 stimulat* OR stimuli* OR stimulu*
#20 (#18 OR #19)
#21 (#11 AND #17 AND #20)
3. Cochrane Epilepsy Group Specialized Register search strategy
#1 MeSH DESCRIPTOR Deep Brain Stimulation Explode All WITH AE CL CT EC ES HI IS MTMONU PX ST SN TDUT VE
#2 (cort* OR brain OR thalam* OR hippocamp* OR cerebel* OR cerebr*) NEAR4 stimul*
#3 “transcranial magnetic stimulation” OR rTMS OR “vagus nerve stimulation” OR “vagal nerve stimulation”
#4 (#1 OR #2) NOT #3
Appendix 3. Quality of life in Tellez-Zenteno 2006
Tellez-Zenteno 2006 reported mean QOLIE-89 scores of 57 (standard deviation (SD) 47), 55 (SD 33) and 27 (SD 60) during baseline,
stimulation ON and stimulated OFF periods. These scores are based on repeated testing (once per month) in 3 patients, resulting in
9 QOLIE-89 scores in total. Tellez-Zenteno 2006 also reported median QOLIE-89 scores (with corresponding interquartile ranges),
being 57 (24 to 90), 64 (30 to 78) and 61 (39 to 80) respectively. Taking into account the total number of QOLIE-89 scores (only
9), the different effect estimators and their corresponding measures of variability, we assume that the authors switched figures for the
QOLIE-89 score during the stimulation OFF period, the mean being 60 and 27 representing the standard deviation. Indeed, it is
impossible to calculate a mean score of 27 when the median is 61 and the interquartile range (39 to 80), with only 9 measurements in
total.
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External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The title of the review was changed from ’Deep brain and cerebellar stimulation for epilepsy’ to ’Deep brain and cortical stimulation for
epilepsy’ as we thought neocortical stimulation also fits the scope of this review (which may be particularly relevant for future updates
of the review).
The percentage seizure frequency reduction was added as an additional outcome measure. This was done in a prespecified way after
one author involved in the writing of the protocol (Annelies Van Dycke) was replaced by another author (MS). The reason to do so
was to allow a more precise estimation of the efficacy of the different invasive intracranial neurostimulation treatments.
We planned to express the treatment effect for dichotomous outcome measures by relative risk (RR). However, for reasons outlined
in the ’Methods’ section, we used odds ratios and performed a sensitivity analysis with RRs to evaluate any possible influence of this
change.
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